<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000966</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>109</s160></s100><s200><s210>1</s210><s211>300</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 1Met Lys Arg Val Ile Thr Leu Phe Ala Val Leu Leu Met Gly Trp Ser1               5                   10                  15Val Asn Ala Trp Ser Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile            20                  25                  30Pro Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val        35                  40                  45Val Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe    50                  55                  60Cys His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln65                  70                  75                  80Arg Gly Ser Ala Tyr Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val                85                  90                  95Lys Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro            100                 105                 110Arg Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu        115                 120                 125Tyr Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly    130                 135                 140Ser Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser145                 150                 155                 160Asp Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val                165                 170                 175Val Pro Thr Gly Gly Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr            180                 185                 190Leu Pro Asp Tyr Pro Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys        195                 200                 205Ala Lys Ser Gln Asn Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp    210                 215                 220Ala Gly Asn Ser Ile Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln225                 230                 235                 240Gly Val Gly Val Gln Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn                245                 250                 255Asn Thr Val Ser Leu Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly            260                 265                 270Leu Thr Ala Asn Tyr Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn        275                 280                 285Val Gln Ser Ile Ile Gly Val Thr Phe Val Tyr Gln    290                 295                 300</s400><s200><s210>2</s210><s211>279</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 2Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu Pro Asp Tyr Pro                165                 170                 175Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala Lys Ser Gln Asn            180                 185                 190Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala Gly Asn Ser Ile        195                 200                 205Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly Val Gly Val Gln    210                 215                 220Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn Asn Thr Val Ser Leu225                 230                 235                 240Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu Thr Ala Asn Tyr                245                 250                 255Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val Gln Ser Ile Ile            260                 265                 270Gly Val Thr Phe Val Tyr Gln        275</s400><s200><s210>3</s210><s211>156</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 3Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val145                 150                 155</s400><s200><s210>4</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 4Gly Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu Pro Asp Tyr1               5                   10                  15Pro Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala Lys Ser Gln            20                  25                  30Asn Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala Gly Asn Ser        35                  40                  45Ile Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly Val Gly Val    50                  55                  60Gln Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn Asn Thr Val Ser65                  70                  75                  80Leu Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu Thr Ala Asn                85                  90                  95Tyr Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val Gln Ser Ile            100                 105                 110Ile Gly Val Thr Phe Val Tyr Gln        115                 120</s400><s200><s210>5</s210><s211>330</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 5Val Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1               5                   10                  15Gly Ser Thr Gly Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro            20                  25                  30Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Cys Val        35                  40                  45Asn Val Gly Gln Asn Cys Val Val Asp Leu Ser Thr Gln Ile Phe Cys    50                  55                  60His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg65                  70                  75                  80Gly Ser Ala Tyr Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys                85                  90                  95Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg            100                 105                 110Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr        115                 120                 125Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser    130                 135                 140Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp145                 150                 155                 160Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val                165                 170                 175Pro Thr Gly Gly Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu            180                 185                 190Pro Asp Tyr Pro Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala        195                 200                 205Lys Ser Gln Asn Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala    210                 215                 220Gly Asn Ser Ile Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly225                 230                 235                 240Val Gly Val Gln Leu Thr Arg Gln Gly Thr Ile Ile Pro Ala Asn Asn                245                 250                 255Thr Val Ser Leu Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu            260                 265                 270Thr Ala Asn Tyr Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val        275                 280                 285Gln Ser Ile Ile Gly Val Thr Phe Val Tyr Gln Gly Gly Ser Ser Gly    290                 295                 300Gly Gly Ala Asp Val Thr Ile Thr Val Asn Gly Lys Val Val Ala Lys305                 310                 315                 320Gly Gly His His His His His His His His                325                 330</s400><s200><s210>6</s210><s211>330</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 6Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1               5                   10                  15Gly Ser Thr Gly Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro            20                  25                  30Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val        35                  40                  45Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys    50                  55                  60His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg65                  70                  75                  80Gly Ser Ala Tyr Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys                85                  90                  95Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg            100                 105                 110Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr        115                 120                 125Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser    130                 135                 140Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp145                 150                 155                 160Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val                165                 170                 175Pro Thr Gly Gly Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu            180                 185                 190Pro Asp Tyr Pro Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala        195                 200                 205Lys Ser Gln Asn Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala    210                 215                 220Gly Asn Ser Ile Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly225                 230                 235                 240Val Gly Val Gln Leu Thr Arg Gln Gly Thr Ile Ile Pro Ala Asn Asn                245                 250                 255Thr Val Ser Leu Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu            260                 265                 270Thr Ala Asn Tyr Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val        275                 280                 285Gln Ser Ile Ile Gly Val Thr Phe Val Tyr Gln Gly Gly Ser Ser Gly    290                 295                 300Gly Gly Ala Asp Val Thr Ile Thr Val Asn Gly Lys Val Val Ala Lys305                 310                 315                 320Gly Gly His His His His His His His His                325                 330</s400><s200><s210>7</s210><s211>188</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 7Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1               5                   10                  15Gly Ser Thr Gly Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro            20                  25                  30Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val        35                  40                  45Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys    50                  55                  60His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg65                  70                  75                  80Gly Ser Ala Tyr Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys                85                  90                  95Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg            100                 105                 110Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr        115                 120                 125Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser    130                 135                 140Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp145                 150                 155                 160Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val                165                 170                 175Pro Thr Gly Gly His His His His His His His His            180                 185</s400><s200><s210>8</s210><s211>188</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 8Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1               5                   10                  15Gly Ser Thr Gly Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro            20                  25                  30Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Cys Val        35                  40                  45Asn Val Gly Gln Asn Cys Val Val Asp Leu Ser Thr Gln Ile Phe Cys    50                  55                  60His Asn Asp Tyr Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg65                  70                  75                  80Gly Ser Ala Tyr Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys                85                  90                  95Tyr Ser Gly Ser Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg            100                 105                 110Val Val Tyr Asn Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr        115                 120                 125Leu Thr Pro Val Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser    130                 135                 140Leu Ile Ala Val Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp145                 150                 155                 160Asp Phe Gln Phe Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val                165                 170                 175Pro Thr Gly Gly His His His His His His His His            180                 185</s400><s200><s210>9</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 9Ala Asp Val Thr Ile Thr Val Asn Gly Lys Val Val Ala Lys1               5                   10</s400><s200><s210>10</s210><s211>241</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 10Met Ser Asn Lys Asn Val Asn Val Arg Lys Ser Gln Glu Ile Thr Phe1               5                   10                  15Cys Leu Leu Ala Gly Ile Leu Met Phe Met Ala Met Met Val Ala Gly            20                  25                  30Arg Ala Glu Ala Gly Val Ala Leu Gly Ala Thr Arg Val Ile Tyr Pro        35                  40                  45Ala Gly Gln Lys Gln Val Gln Leu Ala Val Thr Asn Asn Asp Glu Asn    50                  55                  60Ser Thr Tyr Leu Ile Gln Ser Trp Val Glu Asn Ala Asp Gly Val Lys65                  70                  75                  80Asp Gly Arg Phe Ile Val Thr Pro Pro Leu Phe Ala Met Lys Gly Lys                85                  90                  95Lys Glu Asn Thr Leu Arg Ile Leu Asp Ala Thr Asn Asn Gln Leu Pro            100                 105                 110Gln Asp Arg Glu Ser Leu Phe Trp Met Asn Val Lys Ala Ile Pro Ser        115                 120                 125Met Asp Lys Ser Lys Leu Thr Glu Asn Thr Leu Gln Leu Ala Ile Ile    130                 135                 140Ser Arg Ile Lys Leu Tyr Tyr Arg Pro Ala Lys Leu Ala Leu Pro Pro145                 150                 155                 160Asp Gln Ala Ala Glu Lys Leu Arg Phe Arg Arg Ser Ala Asn Ser Leu                165                 170                 175Thr Leu Ile Asn Pro Thr Pro Tyr Tyr Leu Thr Val Thr Glu Leu Asn            180                 185                 190Ala Gly Thr Arg Val Leu Glu Asn Ala Leu Val Pro Pro Met Gly Glu        195                 200                 205Ser Thr Val Lys Leu Pro Ser Asp Ala Gly Ser Asn Ile Thr Tyr Arg    210                 215                 220Thr Ile Asn Asp Tyr Gly Ala Leu Thr Pro Lys Met Thr Gly Val Met225                 230                 235                 240Glu</s400><s200><s210>11</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 11Asp Asn Lys Gln1</s400><s200><s210>12</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 12Gly Gly Ser Gly Gly1               5</s400><s200><s210>13</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 13Gly Gly Ser Ser Gly Gly1               5</s400><s200><s210>14</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 14Gly Gly Ser Ser Gly Gly Gly1               5</s400><s200><s210>15</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 15Gly Gly Gly Ser Ser Gly Gly Gly1               5</s400><s200><s210>16</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 16Gly Gly Gly Ser Gly Ser Gly Gly Gly1               5</s400><s200><s210>17</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 17Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly1               5                   10</s400><s200><s210>18</s210><s211>21</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 18Met Lys Arg Val Ile Thr Leu Phe Ala Val Leu Leu Met Gly Trp Ser1               5                   10                  15Val Asn Ala Trp Ser            20</s400><s200><s210>19</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 19Val Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1               5                   10                  15Gly Ser Thr Gly            20</s400><s200><s210>20</s210><s211>279</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 20Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Cys Val Asn Val Gly Gln            20                  25                  30Asn Cys Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu Pro Asp Tyr Pro                165                 170                 175Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala Lys Ser Gln Asn            180                 185                 190Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala Gly Asn Ser Ile        195                 200                 205Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly Val Gly Val Gln    210                 215                 220Leu Thr Arg Gln Gly Thr Ile Ile Pro Ala Asn Asn Thr Val Ser Leu225                 230                 235                 240Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu Thr Ala Asn Tyr                245                 250                 255Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val Gln Ser Ile Ile            260                 265                 270Gly Val Thr Phe Val Tyr Gln        275</s400><s200><s210>21</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 21Ala Asp Val Thr Ile Thr Val Asn Gly Lys Val Val Ala Lys Gly Gly1               5                   10                  15His His His His His His His His            20</s400><s200><s210>22</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 22Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1               5                   10                  15Gly Ser Thr Gly            20</s400><s200><s210>23</s210><s211>279</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 23Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu Pro Asp Tyr Pro                165                 170                 175Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala Lys Ser Gln Asn            180                 185                 190Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala Gly Asn Ser Ile        195                 200                 205Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly Val Gly Val Gln    210                 215                 220Leu Thr Arg Gln Gly Thr Ile Ile Pro Ala Asn Asn Thr Val Ser Leu225                 230                 235                 240Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu Thr Ala Asn Tyr                245                 250                 255Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val Gln Ser Ile Ile            260                 265                 270Gly Val Thr Phe Val Tyr Gln        275</s400><s200><s210>24</s210><s211>160</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 24Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160</s400><s200><s210>25</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 25His His His His His His His His1               5</s400><s200><s210>26</s210><s211>160</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 26Phe Ala Cys Lys Thr Ala Ser Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Cys Val Asn Val Gly Gln            20                  25                  30Asn Cys Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160</s400><s200><s210>27</s210><s211>168</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 27Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160His His His His His His His His                165</s400><s200><s210>28</s210><s211>279</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 28Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ser Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Asn Phe Ser Gly Thr Val Lys Tyr Ser Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu Pro Asp Tyr Pro                165                 170                 175Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala Lys Ser Gln Asn            180                 185                 190Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala Gly Asn Ser Ile        195                 200                 205Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly Val Gly Val Gln    210                 215                 220Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn Asn Thr Val Ser Leu225                 230                 235                 240Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu Thr Ala Asn Tyr                245                 250                 255Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val Gln Ser Ile Ile            260                 265                 270Gly Val Thr Phe Val Tyr Gln        275</s400><s200><s210>29</s210><s211>279</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 29Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly Gly Gly1               5                   10                  15Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Ala Val Asn Val Gly Gln            20                  25                  30Asn Leu Val Val Asp Leu Ser Thr Gln Ile Phe Cys His Asn Asp Tyr        35                  40                  45Pro Glu Thr Ile Thr Asp Tyr Val Thr Leu Gln Arg Gly Ala Ala Tyr    50                  55                  60Gly Gly Val Leu Ser Ser Phe Ser Gly Thr Val Lys Tyr Asn Gly Ser65                  70                  75                  80Ser Tyr Pro Phe Pro Thr Thr Ser Glu Thr Pro Arg Val Val Tyr Asn                85                  90                  95Ser Arg Thr Asp Lys Pro Trp Pro Val Ala Leu Tyr Leu Thr Pro Val            100                 105                 110Ser Ser Ala Gly Gly Val Ala Ile Lys Ala Gly Ser Leu Ile Ala Val        115                 120                 125Leu Ile Leu Arg Gln Thr Asn Asn Tyr Asn Ser Asp Asp Phe Gln Phe    130                 135                 140Val Trp Asn Ile Tyr Ala Asn Asn Asp Val Val Val Pro Thr Gly Gly145                 150                 155                 160Cys Asp Val Ser Ala Arg Asp Val Thr Val Thr Leu Pro Asp Tyr Pro                165                 170                 175Gly Ser Val Pro Ile Pro Leu Thr Val Tyr Cys Ala Lys Ser Gln Asn            180                 185                 190Leu Gly Tyr Tyr Leu Ser Gly Thr Thr Ala Asp Ala Gly Asn Ser Ile        195                 200                 205Phe Thr Asn Thr Ala Ser Phe Ser Pro Ala Gln Gly Val Gly Val Gln    210                 215                 220Leu Thr Arg Asn Gly Thr Ile Ile Pro Ala Asn Asn Thr Val Ser Leu225                 230                 235                 240Gly Ala Val Gly Thr Ser Ala Val Ser Leu Gly Leu Thr Ala Asn Tyr                245                 250                 255Ala Arg Thr Gly Gly Gln Val Thr Ala Gly Asn Val Gln Ser Ile Ile            260                 265                 270Gly Val Thr Phe Val Tyr Gln        275</s400><s200><s210>30</s210><s211>325</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 30Met Arg Val Glu Asn Asn Asn Val Ser Gly Gln Asn His Asp Pro Glu1               5                   10                  15Gln Ile Asp Leu Ile Asp Leu Leu Val Gln Leu Trp Arg Gly Lys Met            20                  25                  30Thr Ile Ile Ile Ser Val Ile Val Ala Ile Ala Leu Ala Ile Gly Tyr        35                  40                  45Leu Ala Val Ala Lys Glu Lys Trp Thr Ser Thr Ala Ile Ile Thr Gln    50                  55                  60Pro Asp Val Gly Gln Ile Ala Gly Tyr Asn Asn Ala Met Asn Val Ile65                  70                  75                  80Tyr Gly Gln Ala Ala Pro Lys Val Ser Asp Leu Gln Glu Thr Leu Ile                85                  90                  95Gly Arg Phe Ser Ser Ala Phe Ser Ala Leu Ala Glu Thr Leu Asp Asn            100                 105                 110Gln Glu Glu Pro Glu Lys Leu Thr Ile Glu Pro Ser Val Lys Asn Gln        115                 120                 125Gln Leu Pro Leu Thr Val Ser Tyr Val Gly Gln Thr Ala Glu Gly Ala    130                 135                 140Gln Met Lys Leu Ala Gln Tyr Ile Gln Gln Val Asp Asp Lys Val Asn145                 150                 155                 160Gln Glu Leu Glu Lys Asp Leu Lys Asp Asn Ile Ala Leu Gly Arg Lys                165                 170                 175Asn Leu Gln Asp Ser Leu Arg Thr Gln Glu Val Val Ala Gln Glu Gln            180                 185                 190Lys Asp Leu Arg Ile Arg Gln Ile Gln Glu Ala Leu Gln Tyr Ala Asn        195                 200                 205Gln Glu Gln Val Thr Lys Pro Gln Val Gln Gln Thr Glu Asp Val Thr    210                 215                 220Gln Asp Thr Leu Phe Leu Leu Gly Ser Glu Ala Leu Glu Ser Met Ile225                 230                 235                 240Lys His Glu Ala Thr Arg Pro Leu Val Phe Ser Ser Asn Tyr Tyr Gln                245                 250                 255Thr Arg Gln Asn Leu Leu Asp Ile Glu Ser Leu Lys Val Asp Asp Leu            260                 265                 270Asp Ile His Ala Tyr Arg Tyr Val Met Lys Pro Thr Leu Pro Ile Arg        275                 280                 285Arg Asp Ser Pro Lys Lys Ala Ile Thr Leu Ile Leu Ala Val Leu Leu    290                 295                 300Gly Gly Met Val Gly Ala Gly Ile Val Leu Gly Arg Asn Ala Leu Arg305                 310                 315                 320Asn Tyr Asn Ala Lys                325</s400><s200><s210>31</s210><s211>326</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 31Met Arg Val Glu Asn Asn Asn Val Ser Gly Gln Asn Asn Asp Pro Glu1               5                   10                  15Gln Ile Asp Leu Ile Asp Leu Leu Val Gln Leu Trp Arg Gly Lys Met            20                  25                  30Thr Ile Ile Ile Ser Val Ile Val Ala Ile Ala Leu Ala Ile Gly Tyr        35                  40                  45Leu Ala Val Ala Lys Glu Lys Trp Thr Ser Thr Ala Ile Ile Thr Gln    50                  55                  60Pro Asp Val Gly Gln Ile Ala Gly Tyr Asn Asn Ala Met Asn Val Ile65                  70                  75                  80Tyr Gly Gln Ala Ala Pro Lys Val Ser Asp Leu Gln Glu Thr Leu Ile                85                  90                  95Gly Arg Phe Ser Ser Ala Phe Ser Ala Leu Ala Glu Thr Leu Asp Asn            100                 105                 110Gln Asp Glu Pro Glu Lys Leu Thr Ile Glu Pro Ser Val Lys Asn Gln        115                 120                 125Gln Leu Pro Leu Thr Val Ser Tyr Val Gly Gln Thr Ala Glu Gly Ala    130                 135                 140Gln Met Lys Leu Ala Gln Tyr Ile Gln Gln Val Asp Asp Lys Val Asn145                 150                 155                 160Gln Glu Leu Glu Lys Asp Leu Lys Asp Asn Ile Ala Leu Gly Arg Lys                165                 170                 175Asn Leu Gln Asp Ser Leu Arg Thr Gln Glu Val Val Ala Gln Glu Gln            180                 185                 190Lys Asp Leu Arg Ile Arg Gln Ile Gln Glu Ala Leu Gln Tyr Ala Asn        195                 200                 205Gln Ala Gln Val Thr Lys Pro Gln Ile Gln Gln Thr Gly Glu Asp Ile    210                 215                 220Thr Gln Asp Thr Leu Phe Leu Leu Gly Ser Glu Ala Leu Glu Ser Met225                 230                 235                 240Ile Lys His Glu Ala Thr Arg Pro Leu Val Phe Ser Pro Asn Tyr Tyr                245                 250                 255Gln Thr Arg Gln Asn Leu Leu Asp Ile Glu Ser Leu Lys Val Asp Asp            260                 265                 270Leu Asp Ile His Ala Tyr Arg Tyr Val Met Lys Pro Thr Leu Pro Ile        275                 280                 285Arg Arg Asp Ser Pro Lys Lys Ala Ile Thr Leu Ile Leu Ala Val Leu    290                 295                 300Leu Gly Gly Met Val Gly Ala Gly Ile Val Leu Gly Arg Asn Ala Leu305                 310                 315                 320Arg Asn Tyr Asn Ala Lys                325</s400><s200><s210>32</s210><s211>326</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 32Met Arg Val Glu Asn Asn Asn Val Ser Gly Gln Asn His Asp Pro Glu1               5                   10                  15Gln Ile Asp Leu Ile Asp Leu Leu Val Gln Leu Trp Arg Gly Lys Met            20                  25                  30Thr Ile Ile Ile Ser Val Val Val Ala Ile Ala Leu Ala Ile Gly Tyr        35                  40                  45Leu Ala Val Ala Lys Glu Lys Trp Thr Ser Thr Ala Ile Ile Thr Gln    50                  55                  60Pro Asp Val Gly Gln Ile Ala Gly Tyr Asn Asn Ala Met Asn Val Ile65                  70                  75                  80Tyr Gly Gln Ala Ala Pro Lys Val Ser Asp Leu Gln Glu Thr Leu Ile                85                  90                  95Gly Arg Phe Ser Phe Ala Phe Ser Ala Leu Ala Glu Thr Leu Asp Asn            100                 105                 110Gln Lys Glu Pro Glu Lys Leu Thr Ile Glu Pro Ser Val Lys Asn Gln        115                 120                 125Gln Leu Pro Leu Thr Val Ser Tyr Val Gly Gln Thr Ala Glu Asp Ala    130                 135                 140Gln Met Lys Leu Ala Gln Tyr Ile Gln Gln Val Asp Asp Lys Val Asn145                 150                 155                 160Gln Glu Leu Glu Lys Asp Leu Lys Asp Asn Leu Ala Leu Gly Arg Lys                165                 170                 175Asn Leu Gln Asp Ser Leu Arg Thr Gln Glu Val Val Ala Gln Glu Gln            180                 185                 190Lys Asp Leu Arg Ile Arg Gln Ile Gln Glu Ala Leu Gln Tyr Ala Asn        195                 200                 205Gln Ala Gln Val Thr Lys Pro Gln Ile Gln Gln Thr Gly Glu Asp Ile    210                 215                 220Thr Gln Asp Thr Leu Phe Leu Leu Gly Ser Glu Ala Leu Glu Ser Met225                 230                 235                 240Ile Lys His Glu Ala Thr Arg Pro Leu Val Phe Ser Pro Asn Tyr Tyr                245                 250                 255Gln Thr Arg Gln Asn Leu Leu Asp Ile Glu Asn Leu Lys Val Asp Asp            260                 265                 270Leu Asp Ile His Ala Tyr Arg Tyr Val Met Lys Pro Thr Leu Pro Ile        275                 280                 285Arg Arg Asp Ser Pro Lys Lys Ala Ile Thr Leu Ile Leu Ala Val Leu    290                 295                 300Leu Gly Gly Met Val Gly Ala Gly Ile Val Leu Gly Arg Asn Ala Leu305                 310                 315                 320Arg Asn Tyr Asn Ser Lys                325</s400><s200><s210>33</s210><s211>326</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 33Met Arg Val Glu Asn Asn Asn Val Ser Gly Gln Asn His Asp Pro Glu1               5                   10                  15Gln Ile Asp Leu Ile Asp Leu Leu Val Gln Leu Trp Arg Gly Lys Met            20                  25                  30Thr Ile Ile Ile Ser Val Ile Val Ala Ile Ala Leu Ala Ile Gly Tyr        35                  40                  45Leu Ala Val Ala Lys Glu Lys Trp Thr Ser Thr Ala Ile Ile Thr Gln    50                  55                  60Pro Asp Val Gly Gln Ile Ala Gly Tyr Asn Asn Ala Met Asn Val Ile65                  70                  75                  80Tyr Gly Gln Ala Ala Pro Lys Val Ser Asp Leu Gln Glu Thr Leu Ile                85                  90                  95Gly Arg Phe Ser Ser Ala Phe Ser Ala Leu Ala Glu Thr Leu Asp Asn            100                 105                 110Gln Glu Glu Arg Glu Lys Leu Thr Ile Glu Pro Ser Val Lys Asn Gln        115                 120                 125Gln Leu Pro Leu Thr Val Ser Tyr Val Gly Gln Thr Ala Glu Gly Ala    130                 135                 140Gln Met Lys Leu Ala Gln Tyr Ile Gln Gln Val Asp Asp Lys Val Asn145                 150                 155                 160Gln Glu Leu Glu Lys Asp Leu Lys Asp Asn Ile Ala Leu Gly Arg Lys                165                 170                 175Asn Leu Gln Asp Ser Leu Arg Thr Gln Glu Val Val Ala Gln Glu Gln            180                 185                 190Lys Asp Leu Arg Ile Arg Gln Ile Gln Glu Ala Leu Gln Tyr Ala Asn        195                 200                 205Gln Ala Gln Val Thr Lys Pro Gln Ile Gln Gln Thr Gly Glu Asp Ile    210                 215                 220Thr Gln Asp Thr Leu Phe Leu Leu Gly Ser Glu Ala Leu Glu Ser Met225                 230                 235                 240Ile Lys His Glu Ala Thr Arg Pro Leu Val Phe Ser Pro Asn Tyr Tyr                245                 250                 255Gln Thr Arg Gln Asn Leu Leu Asp Ile Glu Ser Leu Lys Val Asp Asp            260                 265                 270Leu Asp Ile His Ala Tyr Arg Tyr Val Met Lys Pro Met Leu Pro Ile        275                 280                 285Arg Arg Asp Ser Pro Lys Lys Ala Ile Thr Leu Ile Leu Ala Val Leu    290                 295                 300Leu Gly Gly Met Val Gly Ala Gly Ile Val Leu Gly Arg Asn Ala Leu305                 310                 315                 320Arg Asn Tyr Asn Ala Lys                325</s400><s200><s210>34</s210><s211>327</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 34Met Thr Val Asp Ser Asn Thr Ser Ser Gly Arg Gly Asn Asp Pro Glu1               5                   10                  15Gln Ile Asp Leu Ile Glu Leu Leu Leu Gln Leu Trp Arg Gly Lys Met            20                  25                  30Thr Ile Ile Val Ala Val Ile Ile Ala Ile Leu Leu Ala Val Gly Tyr        35                  40                  45Leu Met Ile Ala Lys Glu Lys Trp Thr Ser Thr Ala Ile Ile Thr Gln    50                  55                  60Pro Asp Ala Ala Gln Val Ala Thr Tyr Thr Asn Ala Leu Asn Val Leu65                  70                  75                  80Tyr Gly Gly Asn Ala Pro Lys Ile Ser Glu Val Gln Ala Asn Phe Ile                85                  90                  95Ser Arg Phe Ser Ser Ala Phe Ser Ala Leu Ser Glu Val Leu Asp Asn            100                 105                 110Gln Lys Glu Arg Glu Lys Leu Thr Ile Glu Gln Ser Val Lys Gly Gln        115                 120                 125Ala Leu Pro Leu Ser Val Ser Tyr Val Ser Thr Thr Ala Glu Gly Ala    130                 135                 140Gln Arg Arg Leu Ala Glu Tyr Ile Gln Gln Val Asp Glu Glu Val Ala145                 150                 155                 160Lys Glu Leu Glu Val Asp Leu Lys Asp Asn Ile Thr Leu Gln Thr Lys                165                 170                 175Thr Leu Gln Glu Ser Leu Glu Thr Gln Glu Val Val Ala Gln Glu Gln            180                 185                 190Lys Asp Leu Arg Ile Lys Gln Ile Glu Glu Ala Leu Arg Tyr Ala Asp        195                 200                 205Glu Ala Lys Ile Thr Gln Pro Gln Ile Gln Gln Thr Gln Asp Val Thr    210                 215                 220Gln Asp Thr Met Phe Leu Leu Gly Ser Asp Ala Leu Lys Ser Met Ile225                 230                 235                 240Gln Asn Glu Ala Thr Arg Pro Leu Val Phe Ser Pro Ala Tyr Tyr Gln                245                 250                 255Thr Lys Gln Thr Leu Leu Asp Ile Lys Asn Leu Lys Val Thr Ala Asp            260                 265                 270Thr Val His Val Tyr Arg Tyr Val Met Lys Pro Thr Leu Pro Val Arg        275                 280                 285Arg Asp Ser Pro Lys Thr Ala Ile Thr Leu Val Leu Ala Val Leu Leu    290                 295                 300Gly Gly Met Ile Gly Ala Gly Ile Val Leu Gly Arg Asn Ala Leu Arg305                 310                 315                 320Ser Tyr Lys Pro Lys Ala Leu                325</s400><s200><s210>35</s210><s211>377</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 35Met Ser Ser Leu Asn Ile Lys Gln Gly Ser Asp Ala His Phe Pro Asp1               5                   10                  15Tyr Pro Leu Ala Ser Pro Ser Asn Asn Glu Ile Asp Leu Leu Asn Leu            20                  25                  30Ile Ser Val Leu Trp Arg Ala Lys Lys Thr Val Met Ala Val Val Phe        35                  40                  45Ala Phe Ala Cys Ala Gly Leu Leu Ile Ser Phe Ile Leu Pro Gln Lys    50                  55                  60Trp Thr Ser Ala Ala Val Val Thr Pro Pro Glu Pro Val Gln Trp Gln65                  70                  75                  80Glu Leu Glu Lys Ser Phe Thr Lys Leu Arg Val Leu Asp Leu Asp Ile                85                  90                  95Lys Ile Asp Arg Thr Glu Ala Phe Asn Leu Phe Ile Lys Lys Phe Gln            100                 105                 110Ser Val Ser Leu Leu Glu Glu Tyr Leu Arg Ser Ser Pro Tyr Val Met        115                 120                 125Asp Gln Leu Lys Glu Ala Lys Ile Asp Glu Leu Asp Leu His Arg Ala    130                 135                 140Ile Val Ala Leu Ser Glu Lys Met Lys Ala Val Asp Asp Asn Ala Ser145                 150                 155                 160Lys Lys Lys Asp Glu Pro Ser Leu Tyr Thr Ser Trp Thr Leu Ser Phe                165                 170                 175Thr Ala Pro Thr Ser Glu Glu Ala Gln Thr Val Leu Ser Gly Tyr Ile            180                 185                 190Asp Tyr Ile Ser Thr Leu Val Val Lys Glu Ser Leu Glu Asn Val Arg        195                 200                 205Asn Lys Leu Glu Ile Lys Thr Gln Phe Glu Lys Glu Lys Leu Ala Gln    210                 215                 220Asp Arg Ile Lys Thr Lys Asn Gln Leu Asp Ala Asn Ile Gln Arg Leu225                 230                 235                 240Asn Tyr Ser Leu Asp Ile Ala Asn Ala Ala Gly Ile Lys Lys Pro Val                245                 250                 255Tyr Ser Asn Gly Gln Ala Val Lys Asp Asp Pro Asp Phe Ser Ile Ser            260                 265                 270Leu Gly Ala Asp Gly Ile Glu Arg Lys Leu Glu Ile Glu Lys Ala Val        275                 280                 285Thr Asp Val Ala Glu Leu Asn Gly Glu Leu Arg Asn Arg Gln Tyr Leu    290                 295                 300Val Glu Gln Leu Thr Lys Ala His Val Asn Asp Val Asn Phe Thr Pro305                 310                 315                 320Phe Lys Tyr Gln Leu Ser Pro Ser Leu Pro Val Lys Lys Asp Gly Pro                325                 330                 335Gly Lys Ala Ile Ile Val Ile Leu Ser Ala Leu Ile Gly Gly Met Val            340                 345                 350Ala Cys Gly Gly Val Leu Leu Arg Tyr Ala Met Ala Ser Arg Lys Gln        355                 360                 365Asp Ala Met Met Ala Asp His Leu Val    370                 375</s400><s200><s210>36</s210><s211>377</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 36Met Ser Ser Leu Asn Ile Lys Gln Gly Ser Glu Ala His Phe Pro Glu1               5                   10                  15Tyr Pro Leu Ala Ser Pro Ser Asn Asn Glu Ile Asp Leu Leu Asn Leu            20                  25                  30Ile Glu Val Leu Trp Arg Ala Lys Lys Thr Val Met Ala Val Val Phe        35                  40                  45Ala Phe Ala Cys Ala Gly Leu Leu Ile Ser Phe Ile Leu Pro Gln Lys    50                  55                  60Trp Thr Ser Ala Ala Val Val Thr Pro Pro Glu Pro Val Gln Trp Gln65                  70                  75                  80Glu Leu Glu Lys Thr Phe Thr Lys Leu Arg Val Leu Asp Leu Asp Ile                85                  90                  95Lys Ile Asp Arg Thr Glu Ala Phe Asn Leu Phe Ile Lys Lys Phe Gln            100                 105                 110Ser Val Ser Leu Leu Glu Glu Tyr Leu Arg Ser Ser Pro Tyr Val Met        115                 120                 125Asp Gln Leu Lys Glu Ala Lys Ile Asp Pro Leu Asp Leu His Arg Ala    130                 135                 140Ile Val Ala Leu Ser Glu Lys Met Lys Ala Val Asp Asp Asn Ala Ser145                 150                 155                 160Lys Lys Lys Asp Glu Ser Ala Leu Tyr Thr Ser Trp Thr Leu Ser Phe                165                 170                 175Thr Ala Pro Thr Ser Glu Glu Ala Gln Lys Val Leu Ala Gly Tyr Ile            180                 185                 190Asp Tyr Ile Ser Ala Leu Val Val Lys Glu Ser Ile Glu Asn Val Arg        195                 200                 205Asn Lys Leu Glu Ile Lys Thr Gln Phe Glu Lys Glu Lys Leu Ala Gln    210                 215                 220Asp Arg Ile Lys Thr Lys Asn Gln Leu Asp Ala Asn Ile Gln Arg Leu225                 230                 235                 240Asn Tyr Ser Leu Asp Ile Ala Asn Ala Ala Gly Ile Lys Lys Pro Val                245                 250                 255Tyr Ser Asn Gly Gln Ala Val Lys Asp Asp Pro Asp Phe Ser Ile Ser            260                 265                 270Leu Gly Ala Asp Gly Ile Glu Arg Lys Leu Glu Ile Glu Lys Ala Val        275                 280                 285Thr Asp Val Ala Glu Leu Asn Gly Glu Leu Arg Asn Arg Gln Tyr Leu    290                 295                 300Val Glu Gln Leu Thr Lys Thr Asn Ile Asn Asp Val Asn Phe Thr Pro305                 310                 315                 320Phe Lys Tyr Gln Leu Arg Pro Ser Leu Pro Val Lys Lys Asp Gly Gln                325                 330                 335Gly Lys Ala Ile Ile Val Ile Leu Ser Ala Leu Val Gly Gly Met Val            340                 345                 350Ala Cys Gly Gly Val Leu Leu Arg His Ala Met Ala Ser Arg Lys Gln        355                 360                 365Asp Ala Met Met Ala Asp His Leu Val    370                 375</s400><s200><s210>37</s210><s211>377</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 37Met Ser Ser Leu Asn Ile Lys Gln Gly Ser Asp Ala His Phe Pro Asp1               5                   10                  15Tyr Pro Leu Ala Ser Pro Ser Asn Asn Glu Ile Asp Leu Leu Asn Leu            20                  25                  30Ile Ser Val Leu Trp Arg Ala Lys Lys Thr Val Met Ala Val Val Phe        35                  40                  45Ala Phe Ala Cys Ala Gly Leu Leu Ile Ser Phe Ile Leu Pro Gln Lys    50                  55                  60Trp Thr Ser Ala Ala Val Val Thr Pro Pro Glu Pro Val Gln Trp Gln65                  70                  75                  80Glu Leu Glu Lys Ser Phe Thr Lys Leu Arg Val Leu Asp Leu Asp Ile                85                  90                  95Lys Ile Asp Arg Thr Glu Ala Phe Asn Leu Phe Ile Lys Lys Phe Gln            100                 105                 110Ser Val Ser Leu Leu Glu Glu Tyr Leu Arg Ser Ser Pro Tyr Val Met        115                 120                 125Asp Gln Leu Lys Glu Ala Lys Ile Asp Glu Leu Asp Leu His Arg Ala    130                 135                 140Ile Val Ala Leu Ser Glu Lys Met Lys Ala Val Asp Asp Asn Ala Ser145                 150                 155                 160Lys Lys Lys Asp Glu Pro Ser Leu Tyr Thr Ser Trp Thr Leu Ser Phe                165                 170                 175Thr Ala Pro Thr Ser Glu Glu Ala Gln Thr Val Leu Ser Gly Tyr Ile            180                 185                 190Asp Tyr Ile Ser Thr Leu Val Val Lys Glu Ser Leu Glu Asn Val Arg        195                 200                 205Asn Lys Leu Glu Ile Lys Thr Gln Phe Glu Lys Glu Lys Leu Ala Gln    210                 215                 220Asp Arg Ile Lys Thr Lys Asn Gln Leu Asp Ala Asn Ile Gln Arg Leu225                 230                 235                 240Asn Tyr Ser Leu Asp Ile Ala Asn Ala Ala Gly Ile Lys Lys Pro Val                245                 250                 255Tyr Ser Asn Gly Gln Ala Val Lys Asp Asp Pro Asp Phe Ser Ile Ser            260                 265                 270Leu Gly Ala Asp Gly Ile Glu Arg Lys Leu Glu Ile Glu Lys Ala Val        275                 280                 285Thr Asp Val Ala Glu Leu Asn Gly Glu Leu Arg Asn Arg Gln Tyr Leu    290                 295                 300Val Glu Gln Leu Thr Lys Ala His Val Asn Asp Val Asn Phe Thr Pro305                 310                 315                 320Phe Lys Tyr Gln Leu Ser Pro Ser Leu Pro Val Lys Lys Asp Gly Pro                325                 330                 335Gly Lys Ala Ile Ile Val Ile Leu Ser Ala Leu Ile Gly Gly Met Val            340                 345                 350Ala Cys Gly Gly Val Leu Leu Arg Tyr Ala Met Ala Ser Arg Lys Gln        355                 360                 365Asp Ala Met Met Ala Asp His Leu Val    370                 375</s400><s200><s210>38</s210><s211>377</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 38Met Ser Ser Leu Asn Ile Lys Gln Gly Ser Asp Ala His Phe Pro Asp1               5                   10                  15Tyr Pro Leu Ala Ser Pro Ser Asn Asn Glu Ile Asp Leu Leu Asn Leu            20                  25                  30Ile Ser Val Leu Trp Arg Ala Lys Lys Thr Val Met Ala Val Val Phe        35                  40                  45Ala Phe Ala Cys Ala Gly Leu Leu Ile Ser Phe Ile Leu Pro Gln Lys    50                  55                  60Trp Thr Ser Ala Ala Val Val Thr Pro Pro Glu Pro Val Gln Trp Gln65                  70                  75                  80Glu Leu Glu Lys Thr Phe Thr Lys Leu Arg Val Leu Asp Leu Asp Ile                85                  90                  95Lys Ile Asp Arg Thr Glu Ala Phe Asn Leu Phe Ile Lys Lys Phe Gln            100                 105                 110Ser Val Ser Leu Leu Glu Glu Tyr Leu Arg Ser Ser Pro Tyr Val Met        115                 120                 125Asp Gln Leu Lys Glu Ala Lys Ile Asp Glu Leu Asp Leu His Arg Ala    130                 135                 140Ile Val Ala Leu Ser Glu Lys Met Lys Ala Val Asp Asp Asn Ala Ser145                 150                 155                 160Lys Lys Lys Asp Glu Pro Ser Leu Tyr Thr Ser Trp Thr Leu Ser Phe                165                 170                 175Thr Ala Pro Thr Ser Glu Glu Ala Gln Thr Val Leu Ser Gly Tyr Ile            180                 185                 190Asp Tyr Ile Ser Ala Leu Val Val Lys Glu Ser Ile Glu Asn Val Arg        195                 200                 205Asn Lys Leu Glu Ile Lys Thr Gln Phe Glu Lys Glu Lys Leu Ala Gln    210                 215                 220Asp Arg Ile Lys Met Lys Asn Gln Leu Asp Ala Asn Ile Gln Arg Leu225                 230                 235                 240Asn Tyr Ser Leu Asp Ile Ala Asn Ala Ala Gly Ile Lys Lys Pro Val                245                 250                 255Tyr Ser Asn Gly Gln Ala Val Lys Asp Asp Pro Asp Phe Ser Ile Ser            260                 265                 270Leu Gly Ala Asp Gly Ile Glu Arg Lys Leu Glu Ile Glu Lys Ala Val        275                 280                 285Thr Asp Val Ala Glu Leu Asn Gly Glu Leu Arg Asn Arg Gln Tyr Leu    290                 295                 300Val Glu Gln Leu Thr Lys Ala Asn Ile Asn Asp Val Asn Phe Thr Pro305                 310                 315                 320Phe Lys Tyr Gln Leu Ser Pro Ser Leu Pro Val Lys Lys Asp Gly Pro                325                 330                 335Gly Lys Ala Ile Ile Val Ile Leu Ser Ala Leu Ile Gly Gly Met Val            340                 345                 350Ala Cys Gly Ser Val Leu Leu Arg Tyr Ala Met Ala Ser Arg Lys Gln        355                 360                 365Asp Ala Met Met Ala Asp His Leu Val    370                 375</s400><s200><s210>39</s210><s211>378</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 39Met Pro Ser Leu Asn Val Lys Gln Glu Lys Asn Gln Ser Phe Ala Gly1               5                   10                  15Tyr Ser Leu Pro Pro Ala Asn Ser His Glu Ile Asp Leu Phe Ser Leu            20                  25                  30Ile Glu Val Leu Trp Gln Ala Lys Arg Arg Ile Leu Ala Thr Val Phe        35                  40                  45Ala Phe Ala Cys Val Gly Leu Leu Leu Ser Phe Leu Leu Pro Gln Lys    50                  55                  60Trp Thr Ser Gln Ala Ile Val Thr Pro Ala Glu Ser Val Gln Trp Gln65                  70                  75                  80Gly Leu Glu Arg Thr Leu Thr Ala Leu Arg Val Leu Asp Met Glu Val                85                  90                  95Ser Val Asp Arg Gly Ser Val Phe Asn Leu Phe Ile Lys Lys Phe Ser            100                 105                 110Ser Pro Ser Leu Leu Glu Glu Tyr Leu Arg Ser Ser Pro Tyr Val Met        115                 120                 125Asp Gln Leu Lys Gly Ala Gln Ile Asp Glu Gln Asp Leu His Arg Ala    130                 135                 140Ile Val Leu Leu Ser Glu Lys Met Lys Ala Val Asp Ser Asn Val Gly145                 150                 155                 160Lys Lys Asn Glu Thr Ser Leu Phe Thr Ser Trp Thr Leu Ser Phe Thr                165                 170                 175Ala Pro Thr Arg Glu Glu Ala Gln Lys Val Leu Ala Gly Tyr Ile Gln            180                 185                 190Tyr Ile Ser Asp Ile Val Val Lys Glu Thr Leu Glu Asn Ile Arg Asn        195                 200                 205Gln Leu Glu Ile Lys Thr Arg Tyr Glu Gln Glu Lys Leu Ala Met Asp    210                 215                 220Arg Val Arg Leu Lys Asn Gln Leu Asp Ala Asn Ile Gln Arg Leu His225                 230                 235                 240Tyr Ser Leu Glu Ile Ala Asn Ala Ala Gly Ile Lys Arg Pro Val Tyr                245                 250                 255Ser Asn Gly Gln Ala Val Lys Asp Asp Pro Asp Phe Ser Ile Ser Leu            260                 265                 270Gly Ala Asp Gly Ile Ser Arg Lys Leu Glu Ile Glu Lys Gly Val Thr        275                 280                 285Asp Val Ala Glu Ile Asp Gly Asp Leu Arg Asn Arg Gln Tyr His Val    290                 295                 300Glu Gln Leu Ala Ala Met Asn Val Ser Asp Val Lys Phe Thr Pro Phe305                 310                 315                 320Lys Tyr Gln Leu Ser Pro Ser Leu Pro Val Lys Lys Asp Gly Pro Gly                325                 330                 335Lys Ala Ile Ile Ile Ile Leu Ala Ala Leu Ile Gly Gly Met Met Ala            340                 345                 350Cys Gly Gly Val Leu Leu Arg His Ala Met Val Ser Arg Lys Met Glu        355                 360                 365Asn Ala Leu Ala Ile Asp Glu Arg Leu Val    370                 375</s400><s200><s210>40</s210><s211>22</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 40gaagcaaacc gtacgcgtaa ag                                              22</s400><s200><s210>41</s210><s211>20</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 41cgaccagctc ttacacggcg                                                 20</s400><s200><s210>42</s210><s211>36</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 42gaaataggac cactaataaa tacacaaatt aataac                               36</s400><s200><s210>43</s210><s211>21</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 43ataattgacg atccggttgc c                                               21</s400><s200><s210>44</s210><s211>27</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 44gctatttacg ccctgattgt cttttgt                                         27</s400><s200><s210>45</s210><s211>22</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 45attgagaacc tgcgtaaacg gc                                              22</s400><s200><s210>46</s210><s211>24</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 46tgaagagcgg ttcagataac ttcc                                            24</s400><s200><s210>47</s210><s211>21</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 47cgatccggaa acctcctaca c                                               21</s400><s200><s210>48</s210><s211>26</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 48gattattcgc gcaacgctaa acagat                                          26</s400><s200><s210>49</s210><s211>23</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 49tgatcattga cgatccggta gcc                                             23</s400><s200><s210>50</s210><s211>70</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 50cggtagctgt aaagccaggg gcggtagcgt ggtttaaacc caagcaacag atcggcgtcg     60tcggtatgga                                                            70</s400><s200><s210>51</s210><s211>78</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 51agcttccata ccgacgacgc cgatctgttg cttgggttta aaccacgcta ccgcccctgg     60ctttacagct accgagct                                                   78</s400><s200><s210>52</s210><s211>30</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 52ggtagctgta aagccagggg cggtagcgtg                                      30</s400><s200><s210>53</s210><s211>30</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 53ccataccgac gacgccgatc tgttgcttgg                                      30</s400><s200><s210>54</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 54Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly1               5                   10                  15Ser Thr Gly</s400><s200><s210>55</s210><s211>23</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 55Met Gly Val Pro Arg Pro Gln Pro Trp Ala Leu Gly Leu Leu Leu Phe1               5                   10                  15Leu Leu Pro Gly Ser Leu Gly            20</s400><s200><s210>56</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 56Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr Gly Val1               5                   10                  15Arg Ala</s400><s200><s210>57</s210><s211>25</s211><s212>PRT</s212><s213>Human respiratory syncytial virus A (strain A2)</s213></s200><s400> 57Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr1               5                   10                  15Ala Val Thr Phe Cys Phe Ala Ser Gly            20                  25</s400><s200><s210>58</s210><s211>15</s211><s212>PRT</s212><s213>Influenza A virus (strain A/Japan/305/1957 H2N2)</s213></s200><s400> 58Met Ala Ile Ile Tyr Leu Ile Leu Leu Phe Thr Ala Val Arg Gly1               5                   10                  15</s400><s200><s210>59</s210><s211>207</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 59Met Glu Gly Met Asp Pro Leu Ala Val Leu Ala Glu Ser Arg Leu Leu1               5                   10                  15Pro Leu Leu Thr Val Arg Gly Gly Glu Asp Leu Ala Gly Leu Ala Thr            20                  25                  30Val Leu Glu Leu Met Gly Val Gly Ala Leu Glu Ile Thr Leu Arg Thr        35                  40                  45Glu Lys Gly Leu Glu Ala Leu Lys Ala Leu Arg Lys Ser Gly Leu Leu    50                  55                  60Leu Gly Ala Gly Thr Val Arg Ser Pro Lys Glu Ala Glu Ala Ala Leu65                  70                  75                  80Glu Ala Gly Ala Ala Phe Leu Val Ser Pro Gly Leu Leu Glu Glu Val                85                  90                  95Ala Ala Leu Ala Gln Ala Arg Gly Val Pro Tyr Leu Pro Gly Val Leu            100                 105                 110Thr Pro Thr Glu Val Glu Arg Ala Leu Ala Leu Gly Leu Ser Ala Leu        115                 120                 125Lys Phe Phe Pro Ala Glu Pro Phe Gln Gly Val Arg Val Leu Arg Ala    130                 135                 140Tyr Ala Glu Val Phe Pro Glu Val Arg Phe Leu Pro Thr Gly Gly Ile145                 150                 155                 160Lys Glu Glu His Leu Pro His Tyr Ala Ala Leu Pro Asn Leu Leu Ala                165                 170                 175Val Gly Gly Ser Trp Leu Leu Gln Gly Asp Leu Ala Ala Val Met Lys            180                 185                 190Lys Val Lys Ala Ala Lys Ala Leu Leu Ser Pro Gln Ala Pro Gly        195                 200                 205</s400><s200><s210>60</s210><s211>156</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 60Met Thr Lys Lys Val Gly Ile Val Asp Thr Thr Phe Ala Arg Val Asp1               5                   10                  15Met Ala Glu Ala Ala Ile Arg Thr Leu Lys Ala Leu Ser Pro Asn Ile            20                  25                  30Lys Ile Ile Arg Lys Thr Val Pro Gly Ile Lys Asp Leu Pro Val Ala        35                  40                  45Cys Lys Lys Leu Leu Glu Glu Glu Gly Cys Asp Ile Val Met Ala Leu    50                  55                  60Gly Met Pro Gly Lys Ala Glu Lys Asp Lys Val Cys Ala His Glu Ala65                  70                  75                  80Ser Leu Gly Leu Met Leu Ala Gln Leu Met Thr Asn Lys His Ile Ile                85                  90                  95Glu Val Phe Val His Glu Asp Glu Ala Lys Asp Asp Asp Glu Leu Asp            100                 105                 110Ile Leu Ala Leu Val Arg Ala Ile Glu His Ala Ala Asn Val Tyr Tyr        115                 120                 125Leu Leu Phe Lys Pro Glu Tyr Leu Thr Arg Met Ala Gly Lys Gly Leu    130                 135                 140Arg Gln Gly Arg Glu Asp Ala Gly Pro Ala Arg Glu145                 150                 155</s400><s200><s210>61</s210><s211>156</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 61Met Thr Lys Lys Val Gly Ile Val Asp Thr Thr Phe Ala Arg Val Asp1               5                   10                  15Met Ala Ser Ala Ala Ile Leu Thr Leu Lys Met Glu Ser Pro Asn Ile            20                  25                  30Lys Ile Ile Arg Lys Thr Val Pro Gly Ile Lys Asp Leu Pro Val Ala        35                  40                  45Cys Lys Lys Leu Leu Glu Glu Glu Gly Cys Asp Ile Val Met Ala Leu    50                  55                  60Gly Met Pro Gly Lys Ala Glu Lys Asp Lys Val Cys Ala His Glu Ala65                  70                  75                  80Ser Leu Gly Leu Met Leu Ala Gln Leu Met Thr Asn Lys His Ile Ile                85                  90                  95Glu Val Phe Val His Glu Asp Glu Ala Lys Asp Asp Ala Glu Leu Lys            100                 105                 110Ile Leu Ala Ala Arg Arg Ala Ile Glu His Ala Leu Asn Val Tyr Tyr        115                 120                 125Leu Leu Phe Lys Pro Glu Tyr Leu Thr Arg Met Ala Gly Lys Gly Leu    130                 135                 140Arg Gln Gly Phe Glu Asp Ala Gly Pro Ala Arg Glu145                 150                 155</s400><s200><s210>62</s210><s211>209</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 62Met Ser Thr Ile Asn Asn Gln Leu Lys Ala Leu Lys Val Ile Pro Val1               5                   10                  15Ile Ala Ile Asp Asn Ala Glu Asp Ile Ile Pro Leu Gly Lys Val Leu            20                  25                  30Ala Glu Asn Gly Leu Pro Ala Ala Glu Ile Thr Phe Arg Ser Ser Ala        35                  40                  45Ala Val Lys Ala Ile Met Leu Leu Arg Ser Ala Gln Pro Glu Met Leu    50                  55                  60Ile Gly Ala Gly Thr Ile Leu Asn Gly Val Gln Ala Leu Ala Ala Lys65                  70                  75                  80Glu Ala Gly Ala Thr Phe Val Val Ser Pro Gly Phe Asn Pro Asn Thr                85                  90                  95Val Arg Ala Cys Gln Ile Ile Gly Ile Asp Ile Val Pro Gly Val Asn            100                 105                 110Asn Pro Ser Thr Val Glu Ala Ala Leu Glu Met Gly Leu Thr Thr Leu        115                 120                 125Lys Phe Phe Pro Ala Glu Ala Ser Gly Gly Ile Ser Met Val Lys Ser    130                 135                 140Leu Val Gly Pro Tyr Gly Asp Ile Arg Leu Met Pro Thr Gly Gly Ile145                 150                 155                 160Thr Pro Ser Asn Ile Asp Asn Tyr Leu Ala Ile Pro Gln Val Leu Ala                165                 170                 175Cys Gly Gly Thr Trp Met Val Asp Lys Lys Leu Val Thr Asn Gly Glu            180                 185                 190Trp Asp Glu Ile Ala Arg Leu Thr Arg Glu Ile Val Glu Gln Val Asn        195                 200                 205Pro</s400><s200><s210>63</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 63Met Pro Ile Phe Thr Leu Asn Thr Asn Ile Lys Ala Thr Asp Val Pro1               5                   10                  15Ser Asp Phe Leu Ser Leu Thr Ser Arg Leu Val Gly Leu Ile Leu Ser            20                  25                  30Lys Pro Gly Ser Tyr Val Ala Val His Ile Asn Thr Asp Gln Gln Leu        35                  40                  45Ser Phe Gly Gly Ser Thr Asn Pro Ala Ala Phe Gly Thr Leu Met Ser    50                  55                  60Ile Gly Gly Ile Glu Pro Ser Lys Asn Arg Asp His Ser Ala Val Leu65                  70                  75                  80Phe Asp His Leu Asn Ala Met Leu Gly Ile Pro Lys Asn Arg Met Tyr                85                  90                  95Ile His Phe Val Asn Leu Asn Gly Asp Asp Val Gly Trp Asn Gly Thr            100                 105                 110Thr Phe</s400><s200><s210>64</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 64Met Asn Gln His Ser His Lys Asp Tyr Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Asp Ile Val Asp Ala Cys Val Glu Ala            20                  25                  30Phe Glu Ile Ala Met Ala Ala Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asn Gly Gly Ile Tyr Arg His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Ser Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Arg Tyr Arg Asp Ser Ala Glu His His Arg        115                 120                 125Phe Phe Ala Ala His Phe Ala Val Lys Gly Val Glu Ala Ala Arg Ala    130                 135                 140Cys Ile Glu Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>65</s210><s211>205</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 65Met Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu1               5                   10                  15Arg Ala Asn Ser Val Glu Glu Ala Ile Glu Lys Ala Val Ala Val Phe            20                  25                  30Ala Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala        35                  40                  45Asp Thr Val Ile Lys Ala Leu Ser Val Leu Lys Glu Lys Gly Ala Ile    50                  55                  60Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val65                  70                  75                  80Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile                85                  90                  95Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met            100                 105                 110Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Thr Ile Leu        115                 120                 125Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met    130                 135                 140Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn145                 150                 155                 160Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly                165                 170                 175Val Gly Ser Ala Leu Val Lys Gly Thr Pro Asp Glu Val Arg Glu Lys            180                 185                 190Ala Lys Ala Phe Val Glu Lys Ile Arg Gly Cys Thr Glu        195                 200                 205</s400><s200><s210>66</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 66Met Asn Gln His Ser His Lys Asp Tyr Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Glu Ile Val Asp Ala Cys Val Ser Ala            20                  25                  30Phe Glu Ala Ala Met Ala Asp Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asn Gly Gly Ile Tyr Arg His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Ser Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Arg Tyr Arg Asp Ser Asp Ala His Thr Leu        115                 120                 125Leu Phe Leu Ala Leu Phe Ala Val Lys Gly Met Glu Ala Ala Arg Ala    130                 135                 140Cys Val Glu Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>67</s210><s211>177</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 67Met Phe Thr Lys Ser Gly Asp Asp Gly Asn Thr Asn Val Ile Asn Lys1               5                   10                  15Arg Val Gly Lys Asp Ser Pro Leu Val Asn Phe Leu Gly Asp Leu Asp            20                  25                  30Glu Leu Asn Ser Phe Ile Gly Phe Ala Ile Ser Lys Ile Pro Trp Glu        35                  40                  45Asp Met Lys Lys Asp Leu Glu Arg Val Gln Val Glu Leu Phe Glu Ile    50                  55                  60Gly Glu Asp Leu Ser Thr Gln Ser Ser Lys Lys Lys Ile Asp Glu Ser65                  70                  75                  80Tyr Val Leu Trp Leu Leu Ala Ala Thr Ala Ile Tyr Arg Ile Glu Ser                85                  90                  95Gly Pro Val Lys Leu Phe Val Ile Pro Gly Gly Ser Glu Glu Ala Ser            100                 105                 110Val Leu His Val Thr Arg Ser Val Ala Arg Arg Val Glu Arg Asn Ala        115                 120                 125Val Lys Tyr Thr Lys Glu Leu Pro Glu Ile Asn Arg Met Ile Ile Val    130                 135                 140Tyr Leu Asn Arg Leu Ser Ser Leu Leu Phe Ala Met Ala Leu Val Ala145                 150                 155                 160Asn Lys Arg Arg Asn Gln Ser Glu Lys Ile Tyr Glu Ile Gly Lys Ser                165                 170                 175Trp</s400><s200><s210>68</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 68Met Asn Gln His Ser His Lys Asp Tyr Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Asp Ile Val Asp Gln Cys Val Arg Ala            20                  25                  30Phe Glu Glu Ala Met Ala Asp Ala Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asn Gly Gly Ile Tyr Arg His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Ser Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Arg Tyr Arg Ser Ser Arg Glu His His Glu        115                 120                 125Phe Phe Arg Glu His Phe Met Val Lys Gly Val Glu Ala Ala Ala Ala    130                 135                 140Cys Ile Thr Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>69</s210><s211>201</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 69Met Gly His Thr Lys Gly Pro Thr Pro Gln Gln His Asp Gly Ser Ala1               5                   10                  15Leu Arg Ile Gly Ile Val His Ala Arg Trp Asn Lys Thr Ile Ile Met            20                  25                  30Pro Leu Leu Ile Gly Thr Ile Ala Lys Leu Leu Glu Cys Gly Val Lys        35                  40                  45Ala Ser Asn Ile Val Val Gln Ser Val Pro Gly Ser Trp Glu Leu Pro    50                  55                  60Ile Ala Val Gln Arg Leu Tyr Ser Ala Ser Gln Leu Gln Thr Pro Ser65                  70                  75                  80Ser Gly Pro Ser Leu Ser Ala Gly Asp Leu Leu Gly Ser Ser Thr Thr                85                  90                  95Asp Leu Thr Ala Leu Pro Thr Thr Thr Ala Ser Ser Thr Gly Pro Phe            100                 105                 110Asp Ala Leu Ile Ala Ile Gly Val Leu Ile Lys Gly Glu Thr Met His        115                 120                 125Phe Glu Tyr Ile Ala Asp Ser Val Ser His Gly Leu Met Arg Val Gln    130                 135                 140Leu Asp Thr Gly Val Pro Val Ile Phe Gly Val Leu Thr Val Leu Thr145                 150                 155                 160Asp Asp Gln Ala Lys Ala Arg Ala Gly Val Ile Glu Gly Ser His Asn                165                 170                 175His Gly Glu Asp Trp Gly Leu Ala Ala Val Glu Met Gly Val Arg Arg            180                 185                 190Arg Asp Trp Ala Ala Gly Lys Thr Glu        195                 200</s400><s200><s210>70</s210><s211>237</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 70Met Tyr Glu Val Asp His Ala Asp Val Tyr Asp Leu Phe Tyr Leu Gly1               5                   10                  15Arg Gly Lys Asp Tyr Ala Ala Glu Ala Ser Asp Ile Ala Asp Leu Val            20                  25                  30Arg Ser Arg Thr Pro Glu Ala Ser Ser Leu Leu Asp Val Ala Cys Gly        35                  40                  45Thr Gly Thr His Leu Glu His Phe Thr Lys Glu Phe Gly Asp Thr Ala    50                  55                  60Gly Leu Glu Leu Ser Glu Asp Met Leu Thr His Ala Arg Lys Arg Leu65                  70                  75                  80Pro Asp Ala Thr Leu His Gln Gly Asp Met Arg Asp Phe Gln Leu Gly                85                  90                  95Arg Lys Phe Ser Ala Val Val Ser Met Phe Ser Ser Val Gly Tyr Leu            100                 105                 110Lys Thr Val Ala Glu Leu Gly Ala Ala Val Ala Ser Phe Ala Glu His        115                 120                 125Leu Glu Pro Gly Gly Val Val Val Val Glu Pro Trp Trp Phe Pro Glu    130                 135                 140Thr Phe Ala Asp Gly Trp Val Ser Ala Asp Val Val Arg Arg Asp Gly145                 150                 155                 160Arg Thr Val Ala Arg Val Ser His Ser Val Arg Glu Gly Asn Ala Thr                165                 170                 175Arg Met Glu Val His Phe Thr Val Ala Asp Pro Gly Lys Gly Val Arg            180                 185                 190His Phe Ser Asp Val His Leu Ile Thr Leu Phe His Gln Arg Glu Tyr        195                 200                 205Glu Ala Ala Phe Met Ala Ala Gly Leu Arg Val Glu Tyr Leu Glu Gly    210                 215                 220Gly Pro Ser Gly Arg Gly Leu Phe Val Gly Val Pro Ala225                 230                 235</s400><s200><s210>71</s210><s211>138</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 71Met Gly Met Lys Glu Lys Phe Val Leu Ile Ile Thr His Gly Asp Phe1               5                   10                  15Gly Lys Gly Leu Leu Ser Gly Ala Glu Val Ile Ile Gly Lys Gln Glu            20                  25                  30Asn Val His Thr Val Gly Leu Asn Leu Gly Asp Asn Ile Glu Lys Val        35                  40                  45Ala Lys Glu Val Met Arg Ile Ile Ile Ala Lys Leu Ala Glu Asp Lys    50                  55                  60Glu Ile Ile Ile Val Val Asp Leu Phe Gly Gly Ser Pro Phe Asn Ile65                  70                  75                  80Ala Leu Glu Met Met Lys Thr Phe Asp Val Lys Val Ile Thr Gly Ile                85                  90                  95Asn Met Pro Met Leu Val Glu Leu Leu Thr Ser Ile Asn Val Tyr Asp            100                 105                 110Thr Thr Glu Leu Leu Glu Asn Ile Ser Lys Ile Gly Lys Asp Gly Ile        115                 120                 125Lys Val Ile Glu Lys Ser Ser Leu Lys Met    130                 135</s400><s200><s210>72</s210><s211>154</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 72Met Lys Tyr Asp Gly Ser Lys Leu Arg Ile Gly Ile Leu His Ala Arg1               5                   10                  15Trp Asn Leu Glu Ile Ile Ala Ala Leu Val Ala Gly Ala Ile Lys Arg            20                  25                  30Leu Gln Glu Phe Gly Val Lys Ala Glu Asn Ile Ile Ile Glu Thr Val        35                  40                  45Pro Gly Ser Phe Glu Leu Pro Tyr Gly Ser Lys Leu Phe Val Glu Lys    50                  55                  60Gln Lys Arg Leu Gly Lys Pro Leu Asp Ala Ile Ile Pro Ile Gly Val65                  70                  75                  80Leu Ile Lys Gly Ser Thr Met His Phe Glu Tyr Ile Cys Asp Ser Thr                85                  90                  95Thr His Gln Leu Met Lys Leu Asn Phe Glu Leu Gly Ile Pro Val Ile            100                 105                 110Phe Gly Val Leu Thr Cys Leu Thr Asp Glu Gln Ala Glu Ala Arg Ala        115                 120                 125Gly Leu Ile Glu Gly Lys Met His Asn His Gly Glu Asp Trp Gly Ala    130                 135                 140Ala Ala Val Glu Met Ala Thr Lys Phe Asn145                 150</s400><s200><s210>73</s210><s211>164</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 73Met Ala Val Lys Gly Leu Gly Glu Val Asp Gln Lys Tyr Asp Gly Ser1               5                   10                  15Lys Leu Arg Ile Gly Ile Leu His Ala Arg Trp Asn Arg Lys Ile Ile            20                  25                  30Leu Ala Leu Val Ala Gly Ala Val Leu Arg Leu Leu Glu Phe Gly Val        35                  40                  45Lys Ala Glu Asn Ile Ile Ile Glu Thr Val Pro Gly Ser Phe Glu Leu    50                  55                  60Pro Tyr Gly Ser Lys Leu Phe Val Glu Lys Gln Lys Arg Leu Gly Lys65                  70                  75                  80Pro Leu Asp Ala Ile Ile Pro Ile Gly Val Leu Ile Lys Gly Ser Thr                85                  90                  95Met His Phe Glu Tyr Ile Cys Asp Ser Thr Thr His Gln Leu Met Lys            100                 105                 110Leu Asn Phe Glu Leu Gly Ile Pro Val Ile Phe Gly Val Leu Thr Cys        115                 120                 125Leu Thr Asp Glu Gln Ala Glu Ala Arg Ala Gly Leu Ile Glu Gly Lys    130                 135                 140Met His Asn His Gly Glu Asp Trp Gly Ala Ala Ala Val Glu Met Ala145                 150                 155                 160Thr Lys Phe Asn</s400><s200><s210>74</s210><s211>175</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 74Met Gly Ala Asn Trp Tyr Leu Asp Asn Glu Ser Ser Arg Leu Ser Phe1               5                   10                  15Thr Ser Thr Lys Asn Ala Asp Ile Ala Glu Val His Arg Phe Leu Val            20                  25                  30Leu His Gly Lys Val Asp Pro Lys Gly Leu Ala Glu Val Glu Val Glu        35                  40                  45Thr Glu Ser Ile Ser Thr Gly Ile Pro Leu Arg Asp Met Leu Leu Arg    50                  55                  60Val Leu Val Phe Gln Val Ser Lys Phe Pro Val Ala Gln Ile Asn Ala65                  70                  75                  80Gln Leu Asp Met Arg Pro Ile Asn Asn Leu Ala Pro Gly Ala Gln Leu                85                  90                  95Glu Leu Arg Leu Pro Leu Thr Val Ser Leu Arg Gly Lys Ser His Ser            100                 105                 110Tyr Asn Ala Glu Leu Leu Ala Thr Arg Leu Asp Glu Arg Arg Phe Gln        115                 120                 125Val Val Thr Leu Glu Pro Leu Val Ile His Ala Gln Asp Phe Asp Met    130                 135                 140Val Arg Ala Phe Asn Ala Leu Arg Leu Val Ala Gly Leu Ser Ala Val145                 150                 155                 160Ser Leu Ser Val Pro Val Gly Ala Val Leu Ile Phe Thr Ala Arg                165                 170                 175</s400><s200><s210>75</s210><s211>208</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 75Met Thr Asp Tyr Ile Arg Asp Gly Ser Ala Ile Lys Ala Leu Ser Phe1               5                   10                  15Ala Ile Ile Leu Ala Glu Ala Asp Leu Arg His Ile Pro Gln Asp Leu            20                  25                  30Gln Arg Leu Ala Val Arg Val Ile His Ala Cys Gly Met Val Asp Val        35                  40                  45Ala Asn Asp Leu Ala Phe Ser Glu Gly Ala Gly Lys Ala Gly Arg Asn    50                  55                  60Ala Leu Leu Ala Gly Ala Pro Ile Leu Cys Asp Ala Arg Met Val Ala65                  70                  75                  80Glu Gly Ile Thr Arg Ser Arg Leu Pro Ala Asp Asn Arg Val Ile Tyr                85                  90                  95Thr Leu Ser Asp Pro Ser Val Pro Glu Leu Ala Lys Lys Ile Gly Asn            100                 105                 110Thr Arg Ser Ala Ala Ala Leu Asp Leu Trp Leu Pro His Ile Glu Gly        115                 120                 125Ser Ile Val Ala Ile Gly Asn Ala Pro Thr Ala Leu Phe Arg Leu Phe    130                 135                 140Glu Leu Leu Asp Ala Gly Ala Pro Lys Pro Ala Leu Ile Ile Gly Met145                 150                 155                 160Pro Val Gly Phe Val Gly Ala Ala Glu Ser Lys Asp Glu Leu Ala Ala                165                 170                 175Asn Ser Arg Gly Val Pro Tyr Val Ile Val Arg Gly Arg Arg Gly Gly            180                 185                 190Ser Ala Met Thr Ala Ala Ala Val Asn Ala Leu Ala Ser Glu Arg Glu        195                 200                 205</s400><s200><s210>76</s210><s211>128</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 76Met Ile Thr Val Phe Gly Leu Lys Ser Lys Leu Ala Pro Arg Arg Glu1               5                   10                  15Lys Leu Ala Glu Val Ile Tyr Ser Ser Leu His Leu Gly Leu Asp Ile            20                  25                  30Pro Lys Gly Lys His Ala Ile Arg Phe Leu Cys Leu Glu Lys Glu Asp        35                  40                  45Phe Tyr Tyr Pro Phe Asp Arg Ser Asp Asp Tyr Thr Val Ile Glu Ile    50                  55                  60Asn Leu Met Ala Gly Arg Ser Glu Glu Thr Lys Met Leu Leu Ile Phe65                  70                  75                  80Leu Leu Phe Ile Ala Leu Glu Arg Lys Leu Gly Ile Arg Ala His Asp                85                  90                  95Val Glu Ile Thr Ile Lys Glu Gln Pro Ala His Cys Trp Gly Phe Arg            100                 105                 110Gly Arg Thr Gly Asp Ser Ala Arg Asp Leu Asp Tyr Asp Ile Tyr Val        115                 120                 125</s400><s200><s210>77</s210><s211>235</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 77Met Gly Ser Asp Leu Gln Lys Leu Gln Arg Phe Ser Thr Cys Asp Ile1               5                   10                  15Ser Asp Gly Leu Leu Asn Val Tyr Asn Ile Pro Thr Gly Gly Tyr Phe            20                  25                  30Pro Asn Leu Thr Ala Ile Ser Pro Pro Gln Asn Ser Ser Ile Val Gly        35                  40                  45Thr Ala Tyr Thr Val Leu Phe Ala Pro Ile Asp Asp Pro Arg Pro Ala    50                  55                  60Val Asn Tyr Ile Asp Ser Val Pro Pro Asn Ser Ile Leu Val Leu Ala65                  70                  75                  80Leu Glu Pro His Leu Gln Ser Gln Phe His Pro Phe Ile Lys Ile Thr                85                  90                  95Gln Ala Met Tyr Gly Gly Leu Met Ser Thr Arg Ala Gln Tyr Leu Lys            100                 105                 110Ser Asn Gly Thr Val Val Phe Gly Arg Ile Arg Asp Val Asp Glu His        115                 120                 125Arg Thr Leu Asn His Pro Val Phe Ala Tyr Gly Val Gly Ser Cys Ala    130                 135                 140Pro Lys Ala Val Val Lys Ala Val Gly Thr Asn Val Gln Leu Lys Ile145                 150                 155                 160Leu Thr Ser Asp Gly Val Thr Gln Thr Ile Cys Pro Gly Asp Tyr Ile                165                 170                 175Ala Gly Asp Asn Asn Gly Ile Val Arg Ile Pro Val Gln Glu Thr Asp            180                 185                 190Ile Ser Lys Leu Val Thr Tyr Ile Glu Lys Ser Ile Glu Val Asp Arg        195                 200                 205Leu Val Ser Glu Ala Ile Lys Asn Gly Leu Pro Ala Lys Ala Ala Gln    210                 215                 220Thr Ala Arg Arg Met Val Leu Lys Asp Tyr Ile225                 230                 235</s400><s200><s210>78</s210><s211>162</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 78Met Ser Gly Met Arg Val Tyr Leu Gly Ala Asp His Ala Gly Tyr Glu1               5                   10                  15Leu Lys Gln Ala Ile Ile Ala Phe Leu Lys Met Thr Gly His Glu Pro            20                  25                  30Ile Asp Cys Gly Ala Leu Arg Tyr Asp Ala Asp Asp Asp Tyr Pro Ala        35                  40                  45Phe Cys Ile Ala Ala Ala Thr Arg Thr Val Ala Asp Pro Gly Ser Leu    50                  55                  60Gly Ile Val Leu Gly Gly Ser Gly Asn Gly Glu Gln Ile Ala Ala Asn65                  70                  75                  80Lys Val Pro Gly Ala Arg Cys Ala Leu Ala Trp Ser Val Gln Thr Ala                85                  90                  95Ala Leu Ala Arg Glu His Asn Asn Ala Gln Leu Ile Gly Ile Gly Gly            100                 105                 110Arg Met His Thr Leu Glu Glu Ala Leu Arg Ile Val Lys Ala Phe Val        115                 120                 125Thr Thr Pro Trp Ser Lys Ala Gln Arg His Gln Arg Arg Ile Asp Ile    130                 135                 140Leu Ala Glu Tyr Glu Arg Thr His Glu Ala Pro Pro Val Pro Gly Ala145                 150                 155                 160Pro Ala</s400><s200><s210>79</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 79Met Gly Asp Asp Ala Arg Ile Ala Ala Ile Gly Asp Val Asp Glu Leu1               5                   10                  15Asn Ser Gln Ile Gly Val Leu Leu Ala Glu Pro Leu Pro Asp Asp Val            20                  25                  30Arg Ala Ala Leu Ser Ala Ile Gln His Asp Leu Phe Asp Leu Gly Gly        35                  40                  45Glu Leu Cys Ile Pro Gly His Ala Ala Ile Thr Glu Asp His Leu Leu    50                  55                  60Arg Leu Ala Leu Trp Leu Val His Tyr Asn Gly Gln Leu Pro Pro Leu65                  70                  75                  80Glu Glu Phe Ile Leu Pro Gly Gly Ala Arg Gly Ala Ala Leu Ala His                85                  90                  95Val Cys Arg Thr Val Cys Arg Arg Ala Glu Arg Ser Ile Lys Ala Leu            100                 105                 110Gly Ala Ser Glu Pro Leu Asn Ile Ala Pro Ala Ala Tyr Val Asn Leu        115                 120                 125Leu Ser Asp Leu Leu Phe Val Leu Ala Arg Val Leu Asn Arg Ala Ala    130                 135                 140Gly Gly Ala Asp Val Leu Trp Asp Arg Thr Arg Ala His145                 150                 155</s400><s200><s210>80</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 80Met Ile Leu Ser Ala Glu Gln Ser Phe Thr Leu Arg His Pro His Gly1               5                   10                  15Gln Ala Ala Ala Leu Ala Phe Val Arg Glu Pro Ala Ala Ala Leu Ala            20                  25                  30Gly Val Gln Arg Leu Arg Gly Leu Asp Ser Asp Gly Glu Gln Val Trp        35                  40                  45Gly Glu Leu Leu Val Arg Val Pro Leu Leu Gly Glu Val Asp Leu Pro    50                  55                  60Phe Arg Ser Glu Ile Val Arg Thr Pro Gln Gly Ala Glu Leu Arg Pro65                  70                  75                  80Leu Thr Leu Thr Gly Glu Arg Ala Trp Val Ala Val Ser Gly Gln Ala                85                  90                  95Thr Ala Ala Glu Gly Gly Glu Met Ala Phe Ala Phe Gln Phe Gln Ala            100                 105                 110His Leu Ala Thr Pro Glu Ala Glu Gly Glu Gly Gly Ala Ala Phe Glu        115                 120                 125Val Met Val Gln Ala Ala Ala Gly Val Thr Leu Leu Leu Val Ala Met    130                 135                 140Ala Leu Pro Gln Gly Leu Ala Ala Gly Leu Pro Pro Ala145                 150                 155</s400><s200><s210>81</s210><s211>156</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 81Met Thr Lys Lys Val Gly Ile Val Asp Thr Thr Phe Ala Arg Val Asp1               5                   10                  15Met Ala Ser Ala Ala Ile Leu Thr Leu Lys Met Glu Ser Pro Asn Ile            20                  25                  30Lys Ile Ile Arg Lys Thr Val Pro Gly Ile Lys Asp Leu Pro Val Ala        35                  40                  45Cys Lys Lys Leu Leu Glu Glu Glu Gly Cys Asp Ile Val Met Ala Leu    50                  55                  60Gly Met Pro Gly Lys Lys Glu Lys Asp Lys Val Cys Ala His Glu Ala65                  70                  75                  80Ser Leu Gly Leu Met Leu Ala Gln Leu Met Thr Asn Lys His Ile Ile                85                  90                  95Glu Val Phe Val His Glu Asp Glu Ala Lys Asp Asp Ala Glu Leu Lys            100                 105                 110Ile Leu Ala Ala Arg Arg Ala Ile Glu His Ala Leu Asn Val Tyr Tyr        115                 120                 125Leu Leu Phe Lys Pro Glu Tyr Leu Thr Arg Met Ala Gly Lys Gly Leu    130                 135                 140Arg Gln Gly Phe Glu Asp Ala Gly Pro Ala Arg Glu145                 150                 155</s400><s200><s210>82</s210><s211>209</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 82Met Asp Asp Ile Asn Asn Gln Leu Lys Arg Leu Lys Val Ile Pro Val1               5                   10                  15Ile Ala Ile Asp Asn Ala Glu Asp Ile Ile Pro Leu Gly Lys Val Leu            20                  25                  30Ala Glu Asn Gly Leu Pro Ala Ala Glu Ile Thr Phe Arg Ser Ser Ala        35                  40                  45Ala Val Lys Ala Ile Met Leu Leu Arg Ser Ala Gln Pro Glu Met Leu    50                  55                  60Ile Gly Ala Gly Thr Ile Leu Asn Gly Val Gln Ala Leu Ala Ala Lys65                  70                  75                  80Glu Ala Gly Ala Asp Phe Val Val Ser Pro Gly Phe Asn Pro Asn Thr                85                  90                  95Val Arg Ala Cys Gln Ile Ile Gly Ile Asp Ile Val Pro Gly Val Asn            100                 105                 110Asn Pro Ser Thr Val Glu Gln Ala Leu Glu Met Gly Leu Thr Thr Leu        115                 120                 125Lys Phe Phe Pro Ala Glu Ala Ser Gly Gly Ile Ser Met Val Lys Ser    130                 135                 140Leu Val Gly Pro Tyr Gly Asp Ile Arg Leu Met Pro Thr Gly Gly Ile145                 150                 155                 160Thr Pro Asp Asn Ile Asp Asn Tyr Leu Ala Ile Pro Gln Val Leu Ala                165                 170                 175Cys Gly Gly Thr Trp Met Val Asp Lys Lys Leu Val Arg Asn Gly Glu            180                 185                 190Trp Asp Glu Ile Ala Arg Leu Thr Arg Glu Ile Val Glu Gln Val Asn        195                 200                 205Pro</s400><s200><s210>83</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 83Met Pro Ile Phe Thr Leu Asn Thr Asn Ile Lys Ala Asp Asp Val Pro1               5                   10                  15Ser Asp Phe Leu Ser Leu Thr Ser Arg Leu Val Gly Leu Ile Leu Ser            20                  25                  30Lys Pro Gly Ser Tyr Val Ala Val His Ile Asn Thr Asp Gln Gln Leu        35                  40                  45Ser Phe Gly Gly Ser Thr Asn Pro Ala Ala Phe Gly Thr Leu Met Ser    50                  55                  60Ile Gly Gly Ile Glu Pro Asp Lys Asn Arg Asp His Ser Ala Val Leu65                  70                  75                  80Phe Asp His Leu Asn Ala Met Leu Gly Ile Pro Lys Asn Arg Met Tyr                85                  90                  95Ile His Phe Val Asn Leu Asn Gly Asp Asp Val Gly Trp Asn Gly Thr            100                 105                 110Thr Phe</s400><s200><s210>84</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 84Met Pro Ile Phe Thr Leu Asn Thr Asn Ile Lys Ala Asp Asp Val Pro1               5                   10                  15Ser Asp Phe Leu Ser Leu Thr Ser Arg Leu Val Gly Leu Ile Leu Ser            20                  25                  30Glu Pro Gly Ser Tyr Val Ala Val His Ile Asn Thr Asp Gln Gln Leu        35                  40                  45Ser Phe Gly Gly Ser Thr Asn Pro Ala Ala Phe Gly Thr Leu Met Ser    50                  55                  60Ile Gly Gly Ile Glu Pro Asp Lys Asn Glu Asp His Ser Ala Val Leu65                  70                  75                  80Phe Asp His Leu Asn Ala Met Leu Gly Ile Pro Lys Asn Arg Met Tyr                85                  90                  95Ile His Phe Val Asp Leu Asp Gly Asp Asp Val Gly Trp Asn Gly Thr            100                 105                 110Thr Phe</s400><s200><s210>85</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 85Met Asn Gln His Ser His Lys Asp His Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Asp Ile Val Asp Ala Cys Val Glu Ala            20                  25                  30Phe Glu Ile Ala Met Ala Ala Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asn Gly Gly Ile Tyr Arg His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Asp Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Arg Tyr Arg Asp Ser Asp Glu His His Arg        115                 120                 125Phe Phe Ala Ala His Phe Ala Val Lys Gly Val Glu Ala Ala Arg Ala    130                 135                 140Cys Ile Glu Ile Leu Asn Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>86</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 86Met Asn Gln His Ser His Lys Asp His Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Asp Ile Val Asp Ala Cys Val Glu Ala            20                  25                  30Phe Glu Ile Ala Met Ala Ala Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asp Gly Gly Ile Tyr Asp His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Asp Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Glu Tyr Glu Asp Ser Asp Glu Asp His Glu        115                 120                 125Phe Phe Ala Ala His Phe Ala Val Lys Gly Val Glu Ala Ala Arg Ala    130                 135                 140Cys Ile Glu Ile Leu Asn Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>87</s210><s211>205</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 87Met Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu1               5                   10                  15Arg Ala Asn Ser Val Glu Glu Ala Ile Glu Lys Ala Val Ala Val Phe            20                  25                  30Ala Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala        35                  40                  45Asp Thr Val Ile Lys Ala Leu Ser Val Leu Lys Glu Lys Gly Ala Ile    50                  55                  60Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val65                  70                  75                  80Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile                85                  90                  95Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met            100                 105                 110Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Asp Ile Leu        115                 120                 125Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met    130                 135                 140Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn145                 150                 155                 160Leu Asp Asn Val Cys Glu Trp Phe Lys Ala Gly Val Leu Ala Val Gly                165                 170                 175Val Gly Asp Ala Leu Val Lys Gly Asp Pro Asp Glu Val Arg Glu Lys            180                 185                 190Ala Lys Lys Phe Val Glu Lys Ile Arg Gly Cys Thr Glu        195                 200                 205</s400><s200><s210>88</s210><s211>205</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 88Met Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu1               5                   10                  15Arg Ala Asn Ser Val Glu Glu Ala Ile Glu Lys Ala Val Ala Val Phe            20                  25                  30Ala Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala        35                  40                  45Asp Thr Val Ile Lys Ala Leu Ser Val Leu Lys Glu Lys Gly Ala Ile    50                  55                  60Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val65                  70                  75                  80Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile                85                  90                  95Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met            100                 105                 110Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Asp Ile Leu        115                 120                 125Lys Leu Phe Pro Gly Glu Val Val Gly Pro Glu Phe Val Glu Ala Met    130                 135                 140Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asp145                 150                 155                 160Leu Asp Asp Val Cys Glu Trp Phe Asp Ala Gly Val Leu Ala Val Gly                165                 170                 175Val Gly Asp Ala Leu Val Glu Gly Asp Pro Asp Glu Val Arg Glu Asp            180                 185                 190Ala Lys Glu Phe Val Glu Glu Ile Arg Gly Cys Thr Glu        195                 200                 205</s400><s200><s210>89</s210><s211>205</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 89Met Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu1               5                   10                  15Arg Ala Asn Ser Val Glu Glu Ala Ile Glu Lys Ala Val Ala Val Phe            20                  25                  30Ala Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala        35                  40                  45Asp Thr Val Ile Lys Ala Leu Ser Val Leu Lys Glu Lys Gly Ala Ile    50                  55                  60Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val65                  70                  75                  80Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile                85                  90                  95Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met            100                 105                 110Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Asp Ile Leu        115                 120                 125Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe Val Lys Ala Met    130                 135                 140Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Asn145                 150                 155                 160Leu Asp Asn Val Cys Lys Trp Phe Lys Ala Gly Val Leu Ala Val Gly                165                 170                 175Val Gly Lys Ala Leu Val Lys Gly Lys Pro Asp Glu Val Arg Glu Lys            180                 185                 190Ala Lys Lys Phe Val Lys Lys Ile Arg Gly Cys Thr Glu        195                 200                 205</s400><s200><s210>90</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 90Met Asn Gln His Ser His Lys Asp His Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Glu Ile Val Asp Ala Cys Val Ser Ala            20                  25                  30Phe Glu Ala Ala Met Arg Asp Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asn Gly Gly Ile Tyr Arg His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Asp Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Arg Tyr Arg Asp Ser Asp Ala His Thr Leu        115                 120                 125Leu Phe Leu Ala Leu Phe Ala Val Lys Gly Met Glu Ala Ala Arg Ala    130                 135                 140Cys Val Glu Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>91</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 91Met Asn Gln His Ser His Lys Asp His Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Glu Ile Val Asp Ala Cys Val Ser Ala            20                  25                  30Phe Glu Ala Ala Met Arg Asp Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asp Gly Gly Ile Tyr Asp His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Asp Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Glu Tyr Glu Asp Ser Asp Ala Asp Thr Leu        115                 120                 125Leu Phe Leu Ala Leu Phe Ala Val Lys Gly Met Glu Ala Ala Arg Ala    130                 135                 140Cys Val Glu Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>92</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 92Met Asn Gln His Ser His Lys Asp His Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Glu Ile Val Asp Ala Cys Val Ser Ala            20                  25                  30Phe Glu Ala Ala Met Arg Asp Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Asn Gly Gly Ile Tyr Arg His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asn Gly Met Met Asn Val Gln Leu Asn Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Asn Tyr Asp Lys Ser Lys Ala His Thr Leu        115                 120                 125Leu Phe Leu Ala Leu Phe Ala Val Lys Gly Met Glu Ala Ala Arg Ala    130                 135                 140Cys Val Glu Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>93</s210><s211>156</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(70)..(70)</s222><s223>Xaa is A or K</s223></s220></s200><s400> 93Met Thr Lys Lys Val Gly Ile Val Asp Thr Thr Phe Ala Arg Val Asp1               5                   10                  15Met Ala Ser Ala Ala Ile Leu Thr Leu Lys Met Glu Ser Pro Asn Ile            20                  25                  30Lys Ile Ile Arg Lys Thr Val Pro Gly Ile Lys Asp Leu Pro Val Ala        35                  40                  45Cys Lys Lys Leu Leu Glu Glu Glu Gly Cys Asp Ile Val Met Ala Leu    50                  55                  60Gly Met Pro Gly Lys Xaa Glu Lys Asp Lys Val Cys Ala His Glu Ala65                  70                  75                  80Ser Leu Gly Leu Met Leu Ala Gln Leu Met Thr Asn Lys His Ile Ile                85                  90                  95Glu Val Phe Val His Glu Asp Glu Ala Lys Asp Asp Ala Glu Leu Lys            100                 105                 110Ile Leu Ala Ala Arg Arg Ala Ile Glu His Ala Leu Asn Val Tyr Tyr        115                 120                 125Leu Leu Phe Lys Pro Glu Tyr Leu Thr Arg Met Ala Gly Lys Gly Leu    130                 135                 140Arg Gln Gly Phe Glu Asp Ala Gly Pro Ala Arg Glu145                 150                 155</s400><s200><s210>94</s210><s211>209</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(2)</s222><s223>Xaa is S or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is T or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is A or R</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(85)..(85)</s222><s223>Xaa is T or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(119)..(119)</s222><s223>Xaa is A or Q</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(163)..(163)</s222><s223>Xaa is S or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(189)..(189)</s222><s223>Xaa is T or R</s223></s220></s200><s400> 94Met Xaa Xaa Ile Asn Asn Gln Leu Lys Xaa Leu Lys Val Ile Pro Val1               5                   10                  15Ile Ala Ile Asp Asn Ala Glu Asp Ile Ile Pro Leu Gly Lys Val Leu            20                  25                  30Ala Glu Asn Gly Leu Pro Ala Ala Glu Ile Thr Phe Arg Ser Ser Ala        35                  40                  45Ala Val Lys Ala Ile Met Leu Leu Arg Ser Ala Gln Pro Glu Met Leu    50                  55                  60Ile Gly Ala Gly Thr Ile Leu Asn Gly Val Gln Ala Leu Ala Ala Lys65                  70                  75                  80Glu Ala Gly Ala Xaa Phe Val Val Ser Pro Gly Phe Asn Pro Asn Thr                85                  90                  95Val Arg Ala Cys Gln Ile Ile Gly Ile Asp Ile Val Pro Gly Val Asn            100                 105                 110Asn Pro Ser Thr Val Glu Xaa Ala Leu Glu Met Gly Leu Thr Thr Leu        115                 120                 125Lys Phe Phe Pro Ala Glu Ala Ser Gly Gly Ile Ser Met Val Lys Ser    130                 135                 140Leu Val Gly Pro Tyr Gly Asp Ile Arg Leu Met Pro Thr Gly Gly Ile145                 150                 155                 160Thr Pro Xaa Asn Ile Asp Asn Tyr Leu Ala Ile Pro Gln Val Leu Ala                165                 170                 175Cys Gly Gly Thr Trp Met Val Asp Lys Lys Leu Val Xaa Asn Gly Glu            180                 185                 190Trp Asp Glu Ile Ala Arg Leu Thr Arg Glu Ile Val Glu Gln Val Asn        195                 200                 205Pro</s400><s200><s210>95</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(13)..(13)</s222><s223>Xaa is T or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(33)..(33)</s222><s223>Xaa is K or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(71)..(71)</s222><s223>Xaa is S or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(74)..(74)</s222><s223>Xaa is R or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(101)..(101)</s222><s223>Xaa is N or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(103)..(103)</s222><s223>Xaa is N or D</s223></s220></s200><s400> 95Met Pro Ile Phe Thr Leu Asn Thr Asn Ile Lys Ala Xaa Asp Val Pro1               5                   10                  15Ser Asp Phe Leu Ser Leu Thr Ser Arg Leu Val Gly Leu Ile Leu Ser            20                  25                  30Xaa Pro Gly Ser Tyr Val Ala Val His Ile Asn Thr Asp Gln Gln Leu        35                  40                  45Ser Phe Gly Gly Ser Thr Asn Pro Ala Ala Phe Gly Thr Leu Met Ser    50                  55                  60Ile Gly Gly Ile Glu Pro Xaa Lys Asn Xaa Asp His Ser Ala Val Leu65                  70                  75                  80Phe Asp His Leu Asn Ala Met Leu Gly Ile Pro Lys Asn Arg Met Tyr                85                  90                  95Ile His Phe Val Xaa Leu Xaa Gly Asp Asp Val Gly Trp Asn Gly Thr            100                 105                 110Thr Phe</s400><s200><s210>96</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Y or H</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(82)..(82)</s222><s223>Xaa is N or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(87)..(87)</s222><s223>Xaa is R or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(105)..(105)</s222><s223>Xaa is S or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(119)..(119)</s222><s223>Xaa is R or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(121)..(121)</s222><s223>Xaa is R or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(124)..(124)</s222><s223>Xaa is A or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(126)..(126)</s222><s223>Xaa is H or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(128)..(128)</s222><s223>Xaa is R or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(150)..(150)</s222><s223>Xaa is A or N</s223></s220></s200><s400> 96Met Asn Gln His Ser His Lys Asp Xaa Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Asp Ile Val Asp Ala Cys Val Glu Ala            20                  25                  30Phe Glu Ile Ala Met Ala Ala Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Xaa Gly Gly Ile Tyr Xaa His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Asp Gly Met Met Asn Val Gln Leu Xaa Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Xaa Tyr Xaa Asp Ser Xaa Glu Xaa His Xaa        115                 120                 125Phe Phe Ala Ala His Phe Ala Val Lys Gly Val Glu Ala Ala Arg Ala    130                 135                 140Cys Ile Glu Ile Leu Xaa Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>97</s210><s211>205</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(126)..(126)</s222><s223>Xaa is T or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(139)..(139)</s222><s223>Xaa is Q or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(142)..(142)</s222><s223>Xaa is K or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(160)..(160)</s222><s223>Xaa is N or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(163)..(163)</s222><s223>Xaa is N or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(166)..(166)</s222><s223>Xaa is E or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(169)..(169)</s222><s223>Xaa is D or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(179)..(179)</s222><s223>Xaa is S, D or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(183)..(183)</s222><s223>Xaa is K or E</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(185)..(185)</s222><s223>Xaa is T, D, or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(192)..(192)</s222><s223>Xaa is D or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(195)..(195)</s222><s223>Xaa is A, E, or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(198)..(198)</s222><s223>Xaa is E or K</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(199)..(199)</s222><s223>Xaa is E or K</s223></s220></s200><s400> 97Met Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile Val Ala Val Leu1               5                   10                  15Arg Ala Asn Ser Val Glu Glu Ala Ile Glu Lys Ala Val Ala Val Phe            20                  25                  30Ala Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr Val Pro Asp Ala        35                  40                  45Asp Thr Val Ile Lys Ala Leu Ser Val Leu Lys Glu Lys Gly Ala Ile    50                  55                  60Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys Arg Lys Ala Val65                  70                  75                  80Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu Asp Glu Glu Ile                85                  90                  95Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met Pro Gly Val Met            100                 105                 110Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly His Xaa Ile Leu        115                 120                 125Lys Leu Phe Pro Gly Glu Val Val Gly Pro Xaa Phe Val Xaa Ala Met    130                 135                 140Lys Gly Pro Phe Pro Asn Val Lys Phe Val Pro Thr Gly Gly Val Xaa145                 150                 155                 160Leu Asp Xaa Val Cys Xaa Trp Phe Xaa Ala Gly Val Leu Ala Val Gly                165                 170                 175Val Gly Xaa Ala Leu Val Xaa Gly Xaa Pro Asp Glu Val Arg Glu Xaa            180                 185                 190Ala Lys Xaa Phe Val Xaa Xaa Ile Arg Gly Cys Thr Glu        195                 200                 205</s400><s200><s210>98</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Y or H</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(38)..(38)</s222><s223>Xaa is A or R</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(82)..(82)</s222><s223>Xaa is N or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(87)..(87)</s222><s223>Xaa is R or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(97)..(97)</s222><s223>Xaa is N or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(105)..(105)</s222><s223>Xaa is S, N, or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(119)..(119)</s222><s223>Xaa is R, E, or N</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(121)..(121)</s222><s223>Xaa is R, E, or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(122)..(122)</s222><s223>Xaa is K or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(124)..(124)</s222><s223>Xaa is K or D</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(126)..(126)</s222><s223>Xaa is H or D</s223></s220></s200><s400> 98Met Asn Gln His Ser His Lys Asp Xaa Glu Thr Val Arg Ile Ala Val1               5                   10                  15Val Arg Ala Arg Trp His Ala Glu Ile Val Asp Ala Cys Val Ser Ala            20                  25                  30Phe Glu Ala Ala Met Xaa Asp Ile Gly Gly Asp Arg Phe Ala Val Asp        35                  40                  45Val Phe Asp Val Pro Gly Ala Tyr Glu Ile Pro Leu His Ala Arg Thr    50                  55                  60Leu Ala Glu Thr Gly Arg Tyr Gly Ala Val Leu Gly Thr Ala Phe Val65                  70                  75                  80Val Xaa Gly Gly Ile Tyr Xaa His Glu Phe Val Ala Ser Ala Val Ile                85                  90                  95Xaa Gly Met Met Asn Val Gln Leu Xaa Thr Gly Val Pro Val Leu Ser            100                 105                 110Ala Val Leu Thr Pro His Xaa Tyr Xaa Xaa Ser Xaa Ala Xaa Thr Leu        115                 120                 125Leu Phe Leu Ala Leu Phe Ala Val Lys Gly Met Glu Ala Ala Arg Ala    130                 135                 140Cys Val Glu Ile Leu Ala Ala Arg Glu Lys Ile Ala Ala145                 150                 155</s400><s200><s210>99</s210><s211>142</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 99taatgcttaa gtcgaacaga aagtaatcgt attgtacacg gccgcataat cgaaattaat     60acgactcact ataggggaat tgtgagcgga taacaattcc ccatcttagt atattagtta    120agtataagaa ggagatatac tt                                             142</s400><s200><s210>100</s210><s211>18</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 100taaagaagga gatatcat                                                   18</s400><s200><s210>101</s210><s211>17</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 101tgagaaggag atatcat                                                    17</s400><s200><s210>102</s210><s211>365</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 102Met Gly Val Pro Arg Pro Gln Pro Trp Ala Leu Gly Leu Leu Leu Phe1               5                   10                  15Leu Leu Pro Gly Ser Leu Gly Ala Glu Ser His Leu Ser Leu Leu Tyr            20                  25                  30His Leu Thr Ala Val Ser Ser Pro Ala Pro Gly Thr Pro Ala Phe Trp        35                  40                  45Val Ser Gly Trp Leu Gly Pro Gln Gln Tyr Leu Ser Tyr Asn Ser Leu    50                  55                  60Arg Gly Glu Ala Glu Pro Cys Gly Ala Trp Val Trp Glu Asn Gln Val65                  70                  75                  80Ser Trp Tyr Trp Glu Lys Glu Thr Thr Asp Leu Arg Ile Lys Glu Lys                85                  90                  95Leu Phe Leu Glu Ala Phe Lys Ala Leu Gly Gly Lys Gly Pro Tyr Thr            100                 105                 110Leu Gln Gly Leu Leu Gly Cys Glu Leu Gly Pro Asp Asn Thr Ser Val        115                 120                 125Pro Thr Ala Lys Phe Ala Leu Asn Gly Glu Glu Phe Met Asn Phe Asp    130                 135                 140Leu Lys Gln Gly Thr Trp Gly Gly Asp Trp Pro Glu Ala Leu Ala Ile145                 150                 155                 160Ser Gln Arg Trp Gln Gln Gln Asp Lys Ala Ala Asn Lys Glu Leu Thr                165                 170                 175Phe Leu Leu Phe Ser Cys Pro His Arg Leu Arg Glu His Leu Glu Arg            180                 185                 190Gly Arg Gly Asn Leu Glu Trp Lys Glu Pro Pro Ser Met Arg Leu Lys        195                 200                 205Ala Arg Pro Ser Ser Pro Gly Phe Ser Val Leu Thr Cys Ser Ala Phe    210                 215                 220Ser Phe Tyr Pro Pro Glu Leu Gln Leu Arg Phe Leu Arg Asn Gly Leu225                 230                 235                 240Ala Ala Gly Thr Gly Gln Gly Asp Phe Gly Pro Asn Ser Asp Gly Ser                245                 250                 255Phe His Ala Ser Ser Ser Leu Thr Val Lys Ser Gly Asp Glu His His            260                 265                 270Tyr Cys Cys Ile Val Gln His Ala Gly Leu Ala Gln Pro Leu Arg Val        275                 280                 285Glu Leu Glu Ser Pro Ala Lys Ser Ser Val Leu Val Val Gly Ile Val    290                 295                 300Ile Gly Val Leu Leu Leu Thr Ala Ala Ala Val Gly Gly Ala Leu Leu305                 310                 315                 320Trp Arg Arg Met Arg Ser Gly Leu Pro Ala Pro Trp Ile Ser Leu Arg                325                 330                 335Gly Asp Asp Thr Gly Val Leu Leu Pro Thr Pro Gly Glu Ala Gln Asp            340                 345                 350Ala Asp Leu Lys Asp Val Asn Val Ile Pro Ala Thr Ala        355                 360                 365</s400><s200><s210>103</s210><s211>62</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 103Met Gly Val Pro Arg Pro Gln Pro Trp Ala Leu Gly Leu Leu Leu Phe1               5                   10                  15Leu Leu Pro Gly Ser Leu Gly Phe Ala Cys Lys Thr Ala Asn Gly Thr            20                  25                  30Ala Ile Pro Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala        35                  40                  45Pro Val Val Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser    50                  55                  60</s400><s200><s210>104</s210><s211>574</s211><s212>PRT</s212><s213>Human respiratory syncytial virus A (strain A2)</s213></s200><s400> 104Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr1               5                   10                  15Ala Val Thr Phe Cys Phe Ala Ser Gly Gln Asn Ile Thr Glu Glu Phe            20                  25                  30Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu        35                  40                  45Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile    50                  55                  60Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys65                  70                  75                  80Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu                85                  90                  95Met Gln Ser Thr Pro Pro Thr Asn Asn Arg Ala Arg Arg Glu Leu Pro            100                 105                 110Arg Phe Met Asn Tyr Thr Leu Asn Asn Ala Lys Lys Thr Asn Val Thr        115                 120                 125Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Val    130                 135                 140Gly Ser Ala Ile Ala Ser Gly Val Ala Val Ser Lys Val Leu His Leu145                 150                 155                 160Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys                165                 170                 175Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val            180                 185                 190Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile Val Asn        195                 200                 205Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu Phe Gln    210                 215                 220Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser Val Asn225                 230                 235                 240Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn Ser Glu                245                 250                 255Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys            260                 265                 270Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile        275                 280                 285Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln Leu Pro    290                 295                 300Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro305                 310                 315                 320Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg                325                 330                 335Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe            340                 345                 350Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp        355                 360                 365Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Ile Asn Leu Cys Asn Val    370                 375                 380Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr385                 390                 395                 400Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys                405                 410                 415Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile            420                 425                 430Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Met Asp        435                 440                 445Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly    450                 455                 460Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr Asp Pro465                 470                 475                 480Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn                485                 490                 495Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu            500                 505                 510Leu His Asn Val Asn Ala Gly Lys Ser Thr Thr Asn Ile Met Ile Thr        515                 520                 525Thr Ile Ile Ile Val Ile Ile Val Ile Leu Leu Ser Leu Ile Ala Val    530                 535                 540Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser545                 550                 555                 560Lys Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn                565                 570</s400><s200><s210>105</s210><s211>64</s211><s212>PRT</s212><s213>Human respiratory syncytial virus A (strain A2)</s213></s200><s400> 105Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr1               5                   10                  15Ala Val Thr Phe Cys Phe Ala Ser Gly Phe Ala Cys Lys Thr Ala Asn            20                  25                  30Gly Thr Ala Ile Pro Ile Gly Gly Gly Ser Ala Asn Val Tyr Val Asn        35                  40                  45Leu Ala Pro Val Val Asn Val Gly Gln Asn Leu Val Val Asp Leu Ser    50                  55                  60</s400><s200><s210>106</s210><s211>178</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 106Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr Gly Val1               5                   10                  15Arg Ala Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His            20                  25                  30Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe        35                  40                  45Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu    50                  55                  60Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys65                  70                  75                  80Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro                85                  90                  95Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu            100                 105                 110Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg        115                 120                 125Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn    130                 135                 140Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu145                 150                 155                 160Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile                165                 170                 175Arg Asn</s400><s200><s210>107</s210><s211>57</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 107Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr Gly Val1               5                   10                  15Arg Ala Phe Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly            20                  25                  30Gly Gly Ser Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val        35                  40                  45Gly Gln Asn Leu Val Val Asp Leu Ser    50                  55</s400><s200><s210>108</s210><s211>562</s211><s212>PRT</s212><s213>Influenza A virus (strain A/Japan/305/1957 H2N2)</s213></s200><s400> 108Met Ala Ile Ile Tyr Leu Ile Leu Leu Phe Thr Ala Val Arg Gly Asp1               5                   10                  15Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Lys Val Asp            20                  25                  30Thr Asn Leu Glu Arg Asn Val Thr Val Thr His Ala Lys Asp Ile Leu        35                  40                  45Glu Lys Thr His Asn Gly Lys Leu Cys Lys Leu Asn Gly Ile Pro Pro    50                  55                  60Leu Glu Leu Gly Asp Cys Ser Ile Ala Gly Trp Leu Leu Gly Asn Pro65                  70                  75                  80Glu Cys Asp Arg Leu Leu Ser Val Pro Glu Trp Ser Tyr Ile Met Glu                85                  90                  95Lys Glu Asn Pro Arg Asp Gly Leu Cys Tyr Pro Gly Ser Phe Asn Asp            100                 105                 110Tyr Glu Glu Leu Lys His Leu Leu Ser Ser Val Lys His Phe Glu Lys        115                 120                 125Val Lys Ile Leu Pro Lys Asp Arg Trp Thr Gln His Thr Thr Thr Gly    130                 135                 140Gly Ser Arg Ala Cys Ala Val Ser Gly Asn Pro Ser Phe Phe Arg Asn145                 150                 155                 160Met Val Trp Leu Thr Lys Glu Gly Ser Asp Tyr Pro Val Ala Lys Gly                165                 170                 175Ser Tyr Asn Asn Thr Ser Gly Glu Gln Met Leu Ile Ile Trp Gly Val            180                 185                 190His His Pro Ile Asp Glu Thr Glu Gln Arg Thr Leu Tyr Gln Asn Val        195                 200                 205Gly Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn Lys Arg Ser Thr    210                 215                 220Pro Glu Ile Ala Thr Arg Pro Lys Val Asn Gly Gln Gly Gly Arg Met225                 230                 235                 240Glu Phe Ser Trp Thr Leu Leu Asp Met Trp Asp Thr Ile Asn Phe Glu                245                 250                 255Ser Thr Gly Asn Leu Ile Ala Pro Glu Tyr Gly Phe Lys Ile Ser Lys            260                 265                 270Arg Gly Ser Ser Gly Ile Met Lys Thr Glu Gly Thr Leu Glu Asn Cys        275                 280                 285Glu Thr Lys Cys Gln Thr Pro Leu Gly Ala Ile Asn Thr Thr Leu Pro    290                 295                 300Phe His Asn Val His Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr Val305                 310                 315                 320Lys Ser Glu Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Val Pro Gln                325                 330                 335Ile Glu Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly            340                 345                 350Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His Ser Asn        355                 360                 365Asp Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln Lys Ala    370                 375                 380Phe Asp Gly Ile Thr Asn Lys Val Asn Ser Val Ile Glu Lys Met Asn385                 390                 395                 400Thr Gln Phe Glu Ala Val Gly Lys Glu Phe Gly Asn Leu Glu Arg Arg                405                 410                 415Leu Glu Asn Leu Asn Lys Arg Met Glu Asp Gly Phe Leu Asp Val Trp            420                 425                 430Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg Thr Leu        435                 440                 445Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val Arg Met    450                 455                 460Gln Leu Arg Asp Asn Val Lys Glu Leu Gly Asn Gly Cys Phe Glu Phe465                 470                 475                 480Tyr His Lys Cys Asp Asp Glu Cys Met Asn Ser Val Lys Asn Gly Thr                485                 490                 495Tyr Asp Tyr Pro Lys Tyr Glu Glu Glu Ser Lys Leu Asn Arg Asn Glu            500                 505                 510Ile Lys Gly Val Lys Leu Ser Ser Met Gly Val Tyr Gln Ile Leu Ala        515                 520                 525Ile Tyr Ala Thr Val Ala Gly Ser Leu Ser Leu Ala Ile Met Met Ala    530                 535                 540Gly Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu Gln Cys Arg Ile545                 550                 555                 560Cys Ile</s400><s200><s210>109</s210><s211>54</s211><s212>PRT</s212><s213>Influenza A virus (strain A/Japan/305/1957 H2N2)</s213></s200><s400> 109Met Ala Ile Ile Tyr Leu Ile Leu Leu Phe Thr Ala Val Arg Gly Phe1               5                   10                  15Ala Cys Lys Thr Ala Asn Gly Thr Ala Ile Pro Ile Gly Gly Gly Ser            20                  25                  30Ala Asn Val Tyr Val Asn Leu Ala Pro Val Val Asn Val Gly Gln Asn        35                  40                  45Leu Val Val Asp Leu Ser    50</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000967A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000967</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17363875</doc-number><date>20210630</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>12</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>31</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>7</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>12</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>31</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>7</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>5254</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">DEVELOPMENT OF A NOVEL LIVE ATTENUATED AFRICAN SWINE FEVER VACCINE BASED IN THE DELETION OF GENE A137R</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="obligated-assignee"><addressbook><orgname>The United States of America, as represented by the Secretary of Agriculture</orgname><address><city>Washington</city><state>DC</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>GLADUE</last-name><first-name>DOUGLAS P.</first-name><address><city>GUILFORD</city><state>CT</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>BORCA</last-name><first-name>MANUEL V.</first-name><address><city>WESTBROOK</city><state>CT</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (&#x201c;ASFV-G&#x201d;). An exemplary vaccine comprises the ASFV-G&#x394;A137R modified virus, a recombinant ASFV-G modified by deleting a portion of the A137R ORF rendering the A137R gene nonfunctional.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="70.10mm" wi="158.75mm" file="US20230000967A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="90.09mm" wi="166.45mm" file="US20230000967A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="113.28mm" wi="124.97mm" file="US20230000967A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="113.62mm" wi="134.96mm" file="US20230000967A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">BACKGROUND OF THE INVENTION</heading><heading id="h-0002" level="1">Field of Invention</heading><p id="p-0002" num="0001">The present disclosure provides details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (&#x201c;ASFV-G&#x201d;). An exemplary vaccine comprises the ASFV-G&#x394;A137R modified virus, a recombinant ASFV-G modified by deleting a portion of the A137R ORF rendering the A137R gene nonfunctional.</p><heading id="h-0003" level="1">Background</heading><p id="p-0003" num="0002">African Swine Fever (ASF) is a contagious viral disease of swine. The causative agent, ASF virus (ASFV), is a large enveloped virus containing a double-stranded DNA genome of approximately 190 kilobase pairs. ASFV shares aspects of genome structure and replication strategy with other large double-stranded DNA viruses, including the Poxviridae, lridoviridae and Phycodnaviridae (Costard et al, Phil. Trans. Royal Soc. B, (2009) 364:2683-96). ASFV infections in domestic pigs are often fatal and are characterized by fever, hemorrhages, ataxia and severe depression. However, the course of infection varies, ranging from highly lethal to sub-clinical, depending on the host characteristics and the particular virus strain (Tulman et al, Curr. Top. Microbial. Immunol. (2009) 328:43-87).</p><p id="p-0004" num="0003">Currently, the disease is endemic in more than twenty sub-Saharan African countries. In Europe, ASF is still endemic on the island of Sardinia (Italy) and new outbreaks have been declared in the Caucasus region since 2007, affecting Georgia, Armenia, Azerbaijan and Russia. Outbreaks have been recently reported in Ukraine, Belarus, Lithuania, Latvia and Poland, affecting both wild boar and swine farms. In 2018-2019 ASF spread into China, causing a rapid spread across South-East Asia including Mongolia, Vietnam, Thailand, Timor Leste, Cambodia, Philippines South and North Korea, in both wild boar and domestic swine farms. In 2020 ASF has also spread to wild boar populations in Germany, where ASF is currently only affecting a small containment area in the country. Recent ASF outbreaks pose the risk of further dissemination into neighboring countries. The parental epidemic virus ASFV Georgia 2007/1, is a highly virulent isolate belonging to the genotype II (Chapman et al, Emerging Infect. Dis. (2011) 17:599-605), and is responsible for all the current outbreaks in Asia and Europe, with outbreak viruses having 90% or greater similarity to the parental strain.</p><p id="p-0005" num="0004">Currently, there is no commercial vaccine available for ASF and disease outbreaks are controlled by animal quarantine and slaughter. Attempts to vaccinate animals using infected cell extracts, supernatants of infected pig peripheral blood leukocytes, purified and inactivated virions, infected glutaraldehyde-fixed macrophages, or detergent-treated infected alveolar macrophages failed to induce protective immunity (Coggins, L., Prag. Med. Viral. (1974) 18:48-63; Forman et al, Arch. Viral., (1982) 74:91-100; Kihm et al, (1987) In: <i>African Swine Fever</i>, Becker, Y. (ed), Martinus Nijhoff, Boston, pp 127-44; Mebus, C. A., Adv. Virus Res., (1988) 35:251-69). Homologous protective immunity does develop in pigs surviving viral infection. Pigs surviving acute infection with moderately virulent or attenuated variants of ASFV develop long-term resistance to homologous, but rarely to heterologous, virus challenge (Hamdy and Dardiri, <i>Am. J. Vet. Res</i>. (1984) 45:711-14; Ruiz-Gonzalvo et al, (1981) In: <i>FAO/CEC Expert Consultation in ASF Research</i>, Wilkinson, P. J. (ed), Rome, pp 206-16). Herein, we report the development of a recombinant vaccine in which a portion of the A137R gene has been deleted from the ASFV-G genome. Vaccination of pigs with this virus protected swine from developing ASF. Because there are not ASFV vaccines currently available, the development of any vaccine that may induce protection against the lethal presentation of the disease is of great interest.</p><heading id="h-0004" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0006" num="0005">The present disclosure provides a genetically modified virus, where the virus genome is at least 99% identical to SEQ ID NO: 2. In some instances, the virus genome is at least 99.8% identical to SEQ ID NO:2. In other instances, the viral genome is identical to SEQ ID NO: 2</p><p id="p-0007" num="0006">The present disclosure further provides a vaccine composition against African Swine Fever Virus (ASFV), comprising a genetically modified virus having a virus genome at least 99% identical to SEQ ID NO: 2. In particular embodiments, the ASFV is ASFV-Georgia 2007 isolate (ASFV-G).</p><p id="p-0008" num="0007">Also provided herein is a method for the protection of swine against ASFV, comprising administering to a swine a live attenuated vaccine comprising a genetically modified virus having a virus genome at least 99% identical to SEQ ID NO: 2 in an amount effective to protect said swine from clinical ASFV disease. In particular embodiments, the ASFV is ASFV-Georgia 2007 isolate (ASFV-G). In an additional embodiment the amount effective to protect said swine from clinical ASFV disease is a vaccine comprising 10<sup>2</sup>-10<sup>6 </sup>HAD<sub>50 </sub>of the genetically modified virus.</p><p id="p-0009" num="0008">The present disclosure further provides a recombinant ASFV mutant virus, comprising a synthetic mutation in the A137R open reading frame or in a regulatory element controlling the expression of the A137R protein, resulting in a non-functional genomic A137R gene. In a particular embodiment, the synthetic mutation is a deletion mutation resulting the deletion of one or more nucleotides between positions 55531 and 55779 of SEQ ID NO:1. In an additional embodiment, the synthetic mutation is a frameshift mutation, insertion mutation, nonsense mutation of one or more nucleotides between positions 55531 and 55779 of SEQ ID NO:1. In some embodiments, the mutant ASFV is an ASFV-Georgia isolate. In some embodiments, the mutant ASFV comprises a genome at least 95% or 99% identical to SEQ ID NO: 2. Further provided herein is a vaccine composition against ASFV-G, comprising a recombinant virus of described in this paragraph.</p><p id="p-0010" num="0009">The present disclosure also provides a method for the protection of swine against ASFV, comprising administering to a swine a live attenuated vaccine comprising the recombinant virus having a synthetic mutation in the A137R open reading frame or in a regulatory element controlling the expression of the A137R protein, resulting in a non-functional genomic A137R gene in an amount effective to protect said swine from clinical ASFV disease. In a particular embodiment, the ASFV is ASFV-G. In still another embodiment, the amount effective to protect said swine from clinical ASFV disease is a vaccine comprising at least 10<sup>2 </sup>HAD<sub>50 </sub>of the genetically modified virus.</p><heading id="h-0005" level="1">INCORPORATION BY REFERENCE</heading><p id="p-0011" num="0010">All publications, patents and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0006" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0012" num="0011">The patent application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.</p><p id="p-0013" num="0012">The novel features of the invention are set forth with particularity in the claims. Features and advantages of the present invention are referred to in the following detailed description, and the accompanying drawings of which:</p><p id="p-0014" num="0013"><figref idref="DRAWINGS">FIG. <b>1</b></figref> provides a graphic representation of the cassette used to create the ASFV-G &#x394;A137R recombinant mutant virus.</p><p id="p-0015" num="0014"><figref idref="DRAWINGS">FIG. <b>2</b></figref> provides graphic representation of in vitro growth characteristics of ASFV-G-A A137R and parental ASFV-G. Primary swine macrophage cell cultures were infected (MOI=0.01) with each of the viruses and virus yield titrated at the indicated times post-infection. Data represent means from three independent experiments. Sensitivity of virus detection: &#x3e;1.8 log<sub>10 </sub>HAD<sub>50</sub>/ml.</p><p id="p-0016" num="0015"><figref idref="DRAWINGS">FIG. <b>3</b></figref> provides graphic representation of anti-ASFV antibody (IgM mediated shown in panels in the left column, and IgG mediated shown in panels in the right column) titers detected by ELISA in pigs IM inoculated with either 10<sup>2 </sup>of ASFV-G-A137R (black) or Sentinel animals mock vaccinated housed with vaccinated animals (blue).</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0007" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0017" num="0016">African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for the swine industry. The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been previously reported that were derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFV. However, none of these vaccines have been developed for commercial use. Here we report the discovery that deletion of a previously uncharacterized gene, A137R, from the highly virulent ASFV isolate Georgia isolate (ASFV-G) produces its complete attenuation in swine. Animals inoculated with the virus lacking a functional A137R gene&#x2014;such as the specific ASFV-G-&#x394;A137R mutant described herein&#x2014;administered intramuscularly (IM) remain clinically normal during a 28-day observational period. Importantly, ASFV-G-&#x394;A137R infected animals were protected when challenged with the virulent parental strain ASFV-G.</p><p id="p-0018" num="0017">Preferred embodiments of the present invention are shown and described herein. It will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention. Various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the included claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents are covered thereby.</p><p id="p-0019" num="0018">Technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which the instant invention pertains, unless otherwise defined. Reference is made herein to various materials and methodologies known to those of skill in the art. Standard reference works setting forth the general principles of recombinant DNA technology include Sambrook et al., &#x201c;Molecular Cloning: A Laboratory Manual&#x201d;, 2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y., 1989; Kaufman et al., eds., &#x201c;Handbook of Molecular and Cellular Methods in Biology and Medicine&#x201d;, CRC Press, Boca Raton, 1995; and McPherson, ed., &#x201c;Directed Mutagenesis: A Practical Approach&#x201d;, IRL Press, Oxford, 1991.</p><p id="p-0020" num="0019">Any suitable materials and/or methods known to those of skill can be utilized in carrying out the instant invention. Materials and/or methods for practicing the instant invention are described. Materials, reagents and the like to which reference is made in the following description and examples are obtainable from commercial sources, unless otherwise noted. This invention teaches methods and describes tools for producing genetically altered strains of ASFV.</p><p id="p-0021" num="0020">As used in the specification and claims, use of the singular &#x201c;a&#x201d;, &#x201c;an&#x201d;, and &#x201c;the&#x201d; include plural references unless the context clearly dictates otherwise.</p><p id="p-0022" num="0021">The terms isolated, purified, or biologically pure as used herein, refer to material that is substantially or essentially free from components that normally accompany the referenced material in its native state.</p><p id="p-0023" num="0022">The term &#x201c;about&#x201d; is defined as plus or minus ten percent of a recited value. For example, about 1.0 g means 0.9 g to 1.1 g and all values within that range, whether specifically stated or not.</p><p id="p-0024" num="0023">The term &#x201c;a nucleic acid consisting essentially of&#x201d;, and grammatical variations thereof, means nucleic acids that differ from a reference nucleic acid sequence by 20 or fewer nucleic acid residues and also perform the function of the reference nucleic acid sequence. Such variants include sequences which are shorter or longer than the reference nucleic acid sequence, have different residues at particular positions, or a combination thereof.</p><p id="p-0025" num="0024">The term &#x201c;adjuvant&#x201d; means a substance or vehicle that non-specifically enhances the immune response to an antigen. Adjuvants can include a suspension of minerals (alum, aluminum hydroxide, or phosphate) on which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in mineral oil (for example, Freund's incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity. Immunostimulatory oligonucleotides can also be used as adjuvants (for example, see U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). Adjuvants also include biological molecules, such as costimulatory molecules.</p><p id="p-0026" num="0025">The term &#x201c;administer&#x201d;/&#x201c;administration&#x201d; means any method of providing a subject with a substance, such as a therapeutic agent by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), oral, intraductal, sublingual, rectal, transdermal, intranasal, vaginal and inhalation routes.</p><p id="p-0027" num="0026">The terms &#x201c;coding sequence&#x201d; and &#x201c;coding region&#x201d; as used herein refer to nucleotide sequences and nucleic acid sequences, including both RNA and DNA, that encode genetic information for the synthesis of an RNA, a protein, or any portion of an RNA or protein.</p><p id="p-0028" num="0027">The term &#x201c;effective amount&#x201d; of a composition provided herein refers to the amount of the composition capable of performing the specified function for which an effective amount is expressed. The exact amount required can vary from composition to composition and from function to function, depending on recognized variables such as the compositions and processes involved. An effective amount can be delivered in one or more applications. Thus, it is not possible to specify an exact amount, however, an appropriate &#x201c;effective amount&#x201d; can be determined by the skilled artisan via routine experimentation.</p><p id="p-0029" num="0028">The terms &#x201c;A137R&#x201d;, &#x201c;ASFV A137R&#x201d;, and &#x201c;genomic A137R&#x201d; are synonyms and refer to the gene defined herein as SEQ ID NO: 3, or any version of SEQ ID NO: 3 with base substitutions that result in a protein with a sequence identical to SEQ ID NO: 4). These terms, in the appropriate context, can also refer to modified versions of these SEQ ID NOs, such as those comprising deletions, insertions, and other recombinant modifications. ASFV-G open reading frame A137R encodes a 137 amino acid protein (SEQ ID NO: 4) and is positioned on the reverse strand between nucleotide positions 55531 and 55944 of SEQ ID NO:1 (Wild-type ASFG, sequenced herein; see also Genbank Accession #FR682468.2.</p><p id="p-0030" num="0029">In the context of the present invention, the term &#x201c;non-functional genomic A137R&#x201d; refers to a modified A137R gene, located in the genome of an ASFV, wherein such modification of the ASFV A137R gene results in no ASFV A137R gene product at all or a biologically non-functional ASFV A137R gene product as compared to an unmodified functional ASFV A137R gene. Such modifications can include, but are not limited to, full or partial deletion of the coding sequence, disruption of the open reading frame (e.g., by insertion of a shift mutation or insertion of a nonsense codon), modification of upstream or downstream regulatory elements, and/or any other currently known or conceivable method of inactivating or knocking-out functional expression of such ASFV Il17L gene.</p><p id="p-0031" num="0030">The term &#x201c;immunize&#x201d; means to render a subject protected from an infectious disease, such as by vaccination.</p><p id="p-0032" num="0031">For the purpose of this invention, the &#x201c;sequence identity&#x201d; of two related nucleotide or amino acid sequences, expressed as a percentage, refers to the number of positions in the two optimally aligned sequences which have identical residues (&#xd7;100) divided by the number of positions compared. A gap, i.e., a position in an alignment where a residue is present in one sequence but not in the other is regarded as a position with non-identical residues. The alignment of the two sequences is performed by the Needleman and Wunsch algorithm (Needleman and Wunsch, J Mol Biol, (1970) 48:3, 443-53). A computer-assisted sequence alignment can be conveniently performed using a standard software program such as GAP which is part of the Wisconsin Package Version 10.1 (Genetics Computer Group, Madison, Wis., USA) using the default scoring matrix with a gap creation penalty of 50 and a gap extension penalty of 3.</p><p id="p-0033" num="0032">The phrase &#x201c;high percent identical&#x201d; or &#x201c;high percent identity&#x201d;, and grammatical variations thereof in the context of two polynucleotides or polypeptides, refers to two or more sequences or sub-sequences that have at least about 80%, identity, at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% nucleotide or amino acid identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. In one exemplary embodiment, the sequences are high percent identical over the entire length of the polynucleotide or polypeptide sequences.</p><p id="p-0034" num="0033">The term &#x201c;swine&#x201d; can generally refer to any member of the Suidae family and includes domesticated and wild pigs, hogs and boars.</p><p id="p-0035" num="0034">A &#x201c;vaccine&#x201d; is herein defined as a biological agent capable of providing a protective response in an animal to which it has been delivered but not capable of causing a serious disease. Administration of the vaccine results in immunity from the disease. Thus, the vaccine stimulates antibody production or cellular immunity against the disease-causing pathogen (e.g., ASFV). Immunity is herein defined as the induction of significantly higher levels of protection against lethality and clinical symptoms following vaccination in a swine population, as compared to the non-vaccinated group. In particular, the vaccine according to the invention protects most of the vaccinated animals against the development of clinical symptoms and lethality of the disease. The vaccine of the present disclosure is typically a genetically engineered (recombinant) mutant virus vaccine.</p><p id="p-0036" num="0035">In the context of the present disclosure, the term &#x201c;non-deficient in its replication&#x201d; refers to a non-naturally occurring recombinant ASFV which is able to replicate in vitro and/or in vivo and/or is capable of producing viral progeny although such replication and/or viral progeny production may also occur at reduced levels compared to the unmodified parent strain. Therefore, it can be the case that such ASFV is non deficient in its replication in vitro, e.g. in a cell culture, although in vivo in a mammal such ASFV is at least partially impaired in its replication, e.g. resulting in a replication and/or viral progeny production below detection limits.</p><p id="p-0037" num="0036">As used herein, the term &#x201c;minimal dose&#x201d; or &#x201c;minimal effective dose&#x201d; refers to a dose that demonstrates the absence of, or minimal presence of, toxicity to the recipient, but still results in producing a desired result (e.g., protective immunity).</p><p id="p-0038" num="0037">Viruses/Vaccines</p><p id="p-0039" num="0038">Provided herein is a novel mutant ASFV-G &#x394;A137R virus (SEQ ID NO: 2), resulting from the recombinant deletion of a portion of the A137R gene (SEQ ID NO: 3) of the parental ASFV-G genome (SEQ ID NO: 1). The genomic nucleotide sequence of a specific recombinant mutant ASFV-G &#x394;A137R (SEQ ID NO: 2) is described herein and differs from the genomic nucleotide sequence encoding the parental ASFV-G (SEQ ID NO: 1). The ASFV-G A137R-encoded protein of 137 amino acids (SEQ ID NO: 4) differs from the predicted mutant A137R protein encoded by the mutant nucleotide sequence of ASFV-G &#x394;A137R. The A137R protein (SEQ ID NO: 6) from ASFV-G&#x394;A137R is predicted to lack amino acids 1 through 85 of the wild-type A137R protein. Because the p72Mcherry Cassette is inserted in this position (see Examples section), it is not believed that the remaining coding region is transcribed, resulting in no functional A137R protein being produced during viral infection.</p><p id="p-0040" num="0039">The exemplary mutant strain (ASFV-G&#x394;A137R (SEQ ID NO: 2)) is representative of the genus of recombinant vaccines in which the ASFV A137R gene is non-functional, which includes, without limitation, deletion mutants, nonsense mutants, insertional mutants, frameshift mutants and other mutants resulting in non-expression of the A137R protein, or expression of a non-functional A137R protein. Other recombinant viruses envisioned include mutants in regulatory elements resulting in non-expression or non-translation of the A137R protein.</p><p id="p-0041" num="0040">Modifications intended to preclude functional expression of a target protein (e.g., A137R) or reduced expression or reduced activity of a target protein can involve mutations of the DNA or gene encoding the target protein, including deletion of all or a portion of a target gene, including but not limited to the open reading frame of a target locus, transcriptional regulators such as promoters of a target locus, and any other regulatory nucleic acid sequences positioned 5&#x2032; or 3&#x2032; from the open reading frame, insertion of premature stop codons in the open reading frame, and insertions or deletions that shift the reading frame leading to premature termination of translation. Such deletional mutations can be achieved using any technique known to those of skill in the art. Reduced levels of the target protein or reduced activity of the target protein may also be achieved with point mutations or insertions in the DNA or gene encoding the target protein. Mutational, insertional, and deletional variants of the disclosed nucleotide sequences and genes can be readily prepared by methods which are well known to those skilled in the art. Techniques used to achieve reduced levels and/or reduced activity of the target protein may include CRISPR/Cas, TALEN, and Zn-finger nuclease. It is well within the skill of a person trained in this art to make mutational, insertional, and deletional mutations which are equivalent in function to the specific ones disclosed herein.</p><p id="p-0042" num="0041">The approaches described herein that were used to create a deletion mutant of A137R in ASFV-G can be used in different isolates of ASFV (such as isolates circulating in Asia, Europe or Africa), where a functional A137R is present. Such approaches can be varied by methodologies known in the art, such as using different selection markers that can select recombinant virus by purification such as, but not limited to, fluorescent proteins, enzymes such as beta-glucuronidase or beta-galactosidase that can be used with chromogenic substrates, and drug selection makers. Such approaches can also be used to create any mutation to the ORF of A137R as well as to regulatory elements controlling the expression and translation of the A137R gene that results in a non-functional A137R protein.</p><p id="p-0043" num="0042">Mutants of A137R (and related strain-specific alleles) in other ASFV strains and genotypes is also encompassed by the present disclosure. Any ASFV known in the art, or later discovered, is contemplated as a potential platform for the construction of such synthetic mutations. ASFV strains comprising synthetic mutations in nucleic acid sequences that exhibit at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 3 are encompassed in the instant invention. ASFV strains comprising entire genomes with 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or higher identity to SEQ ID NO: 2 are also encompassed in the instant invention.</p><p id="p-0044" num="0043">The present disclosure further contemplates the combination of a non-functional A137R gene with other recombinant mutations. As such, it is not only wild-type viruses that can be modified as disclosed herein, but also strains containing non-naturally occurring mutations in other genes or genomic regions (see, e.g., U.S. Pat. No. 9,814,771).</p><p id="p-0045" num="0044">The present disclosure provides that such rationally-designed, live, attenuated ASFV-G &#x394;A137R can be incorporated into immunogenic compositions to produce a vaccine effective to protect an animal, such as a pig, from clinical ASF disease when challenged with ASFV-G. Thus, one object of the invention is to provide a method for protecting an animal against ASFV-G by administering an effective amount of rationally designed live attenuated ASFV-G&#x394;A137R vaccine. In another embodiment, the present disclosure provides a method for eliciting a protective immune response in an animal, preferably of the family Suidae (e.g., domestic pigs (<i>Sus scrofa domesticus</i>), wild pigs (<i>Sus scrofa scrofa</i>), warthogs (<i>Potamochoerus porcus</i>), bushpigs (<i>Potamochoerus larvatus</i>), giant forest hogs (<i>Hylochoerus meinertzhageni</i>) as well as feral pigs), Such methods will typically comprise administering to such animal the one or more ASFV immunogenic compositions and vaccines described herein.</p><p id="p-0046" num="0045">An additional object of the present disclosure is to provide a method for distinguishing animals infected with a wild-type ASFV from animals vaccinated with a recombinant virus described herein. Such methodologies for differentiating infected from vaccinated animals (DIVA) can be accomplished by serological tests that detect the difference between wild-type A137R protein and a mutant A137R protein. Alternately, such methodologies can include genetic screening approaches such as PCR amplification and detection of different products based. Typically, such approaches utilize one or more primer sets that flank the site of a mutation and expand the same region, resulting in products of different lengths or sequences.</p><p id="p-0047" num="0046">The immunogenic composition(s) of the invention herein, regardless of other components included, comprise a recombinant ASFV with a non-functional A137R gene/protein. A137R proteins of the present invention can comprise the entirety of SEQ ID NO: 4 and proteins with 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity to the protein of SEQ ID NO: 4.</p><p id="p-0048" num="0047">The immunogenically effective amounts of immunogenic compositions disclosed herein can vary based upon multiple parameters. In general, however, effective amounts per dosage unit for intramuscular application can be about 10<sup>2 </sup>50% hemadsorption dose (&#x201c;HAD<sub>50</sub>&#x201d;) to 10<sup>6 </sup>HAD<sub>50</sub>. One, two, or more dosage units can be utilized in practicing the methodologies of the present invention. A dosage unit can readily be modified to fit a desired volume or mass by one of skill in the art. Regardless of the dosage unit parameters, immunogenic compositions disclosed herein can be administered in an amount effective to produce an immune response.</p><p id="p-0049" num="0048">Dosage levels of active ingredients in vaccines disclosed herein, can be varied by one of skill in the art to achieve a desired result in a subject or per application. As such, a selected dosage level can depend upon a variety of factors including, but not limited to, formulation, combination with other treatments, severity of a pre-existing condition, and the presence or absence of adjuvants. In preferred embodiments, a minimal dose of an immunogenic composition is administered. Determination of a minimal dose is well within the capabilities of one skilled in the art.</p><p id="p-0050" num="0049">Vaccines of the present invention can be prepared by conventional methods used for commercially available live attenuated ASFV vaccines. In a specific embodiment, a susceptible substrate is inoculated with an ASFV-G&#x394;A137R mutant and propagated until the virus has replicated to a desired titer after which ASFV-G&#x394;A137R-containing material is harvested. Following this, the harvested material can be formulated into a vaccine preparation with immunogenic properties. Every substrate which is able to support the replication of the recombinant viruses provided herein can be used in the present invention, including primary cultures of swine peripheral blood macrophages or blood from infected swine.</p><p id="p-0051" num="0050">Formulations and Administration</p><p id="p-0052" num="0051">A vaccine provided herein comprises one of the recombinant viruses as defined above in a live form, and a pharmaceutically acceptable carrier or diluent customarily used for such compositions. Carriers include stabilizers, preservatives and buffers. Suitable stabilizers include, for example, SPGA (sucrose, phosphate, glutamate and albumin), carbohydrates (sorbitol, mannitol, starch, sucrose, dextran, glutamate, and glucose), proteins (dried milk, serum, albumin, casein), or degradation products thereof. Suitable buffers include, for example alkali metal phosphates. Preservatives that can be utilized, include, but are not limited to, thimerosal, merthiolate and gentamicin. Diluents include water, aqueous buffers (e.g., buffered saline), alcohols and polyols (e.g., glycerol).</p><p id="p-0053" num="0052">In some instances, vaccines of the present invention also contain or comprise one or more adjuvants, which includes any material included in the immunogenic composition formulation that enhances an immune response in the recipient that is induced by the immunogenic composition. In some instances, such adjuvants can include proteins other components included with the recombinant virus. Other adjuvants can be included as an extra component of the immunogenic compositions, and include such categories as aluminum salts (alum), oil emulsions, saponins, immune-stimulating complexes (ISCOMs), liposomes, microparticles, nonionic block copolymers, derivatized polysaccharides, cytokines, and a wide variety of bacterial derivatives. Any relevant adjuvant known in the art can be utilized in practicing the inventions disclosed herein. Factors influencing the selection of an adjuvant include animal species, specific pathogen, antigen, route of immunization, and type of immunity needed and can be readily determined by one of skill in the art.</p><p id="p-0054" num="0053">Immunogenic compositions of the present disclosure can also comprise carriers in addition to the recombinant virus. Carriers utilized in practicing the immunogenic compositions provided herein can be any known in the art and can be liquid, solid, semi-solid, or gel. The type of formulation can be modified depending on the route of administration of the antigen. Preferably, carriers are non-toxic to the recipient. One of skill in the art is readily able to choose such carriers for application to recipient animals such as poultry.</p><p id="p-0055" num="0054">The present disclosure provides immunogenic compositions for introducing a recombinant ASFV lacking a functional A137R gene/protein in a composition containing, at a minimum, the recombinant virus, into targets (e.g., swine). Thus, the compositions provided herein can be utilized to induce immunity or resistance to ASFV disease.</p><p id="p-0056" num="0055">Vaccines provided herein may be administered by intramuscular, subcutaneous, intranasal or injection in an amount which is effective to protect the animal against challenge by a virulent strain of ASFV. The vaccine may be administered orally, through direct oral inoculation, dosed in drinking water, or though bait delivery systems. The effective amount of recombinant virus may vary according to parameters considered by those skilled in the art. Effective amounts can be experimentally determined as necessary by those of skill in the art by following any known method or the guidance provided in the Examples herein.</p><p id="p-0057" num="0056">As originally described, the ASFV A137R gene encodes for a 137 amino acid protein A137 (Alcami et al, J. Gen. Virol. (1993), 11:2317-24). The translated product of the ASFV A137R gene is a protein expressed late during the virus replication cycle, with a electrophoretic mobility of 11.5 KD and has been detected in preparations of purified virus (Alejo et al, J. Virol., (2018) 92:e01293-18). The protein is highly conserved and found in all isolates of ASF. Not much is known about A137, other than it is translated at late times of infection and incorporated into the virus particle. To date, no role in pathogenesis has been conducted and no mutant phenotypes have been described.</p><p id="p-0058" num="0057">Having generally described this invention, the same will be better understood by reference to certain specific examples, which are included herein to further illustrate the invention and are not intended to limit the scope of the invention as defined by the claims.</p><heading id="h-0008" level="1">EXAMPLES</heading><heading id="h-0009" level="1">Example 1</heading><p id="p-0059" num="0058">Cell Culture and Viruses.</p><p id="p-0060" num="0059">Primary swine macrophage cell cultures were prepared from defibrinated swine blood as previously described (Zsak et al, J. Virol., (1998) 72:1028-35). Briefly, heparin-treated swine blood was incubated at 37&#xb0; C. for 1 hour to allow sedimentation of the erythrocyte fraction. Mononuclear leukocytes were separated by flotation over a Ficoll-Paque (Pharmacia, Piscataway, N.J.) density gradient (specific gravity, 1.079). The monocyte/macrophage cell fraction was cultured in plastic Primaria (Falcon; Becton Dickinson Labware, Franklin Lakes, N.J.) tissue culture flasks containing macrophage media, composed of RPMI 1640 Medium (Life Technologies, Grand Island, N.Y.) with 30% L929 supernatant and 20% fetal bovine serum (HI-FBS, Thermo Scientific, Waltham, Mass.) for 48 hours at 37&#xb0; C. under 5% CO2. Adherent cells were detached from the plastic by using 10 mM EDTA in phosphate buffered saline (PBS) and were then reseeded into Primaria T25, 6- or 96-well dishes at a density of 5&#xd7;10<sup>6 </sup>cells per ml for use in assays 24 hours later.</p><p id="p-0061" num="0060">Virus titration was performed on primary swine macrophage cell cultures in 96-well plates. Virus dilutions and cultures were performed using macrophage medium. Presence of virus was assessed by hemadsorption (HA) and virus titers were calculated by the Reed and Muench method (Amer. J. Hygiene, (1938) 27:493-497).</p><p id="p-0062" num="0061">ASFV Georgia (ASFV-G) utilized for this study was a field isolate kindly provided by Dr. Nino Vepkhvadze, from the Laboratory of the Ministry of Agriculture (LMA) in Tbilisi, Republic of Georgia.</p><heading id="h-0010" level="1">Example 2</heading><p id="p-0063" num="0062">Construction of a Recombinant ASFV-G &#x394;A137R</p><p id="p-0064" num="0063">Recombinant ASFVs were generated by sequential homologous recombination between the parental ASFV genome and recombination transfer vectors in infection and transfection procedures using swine macrophage cell cultures (Neilan et al, Virol., (2004) 319:337-42; Zsak et al, supra). Recombinant transfer vector (p72mCherry&#x394;A137R) containing flanking genomic regions including portions of A137R mapping to the left (1 kbp) and right (1 kbp) of the gene and a reporter gene cassette containing the mCherry gene with the ASFV p72 late gene promoter, p72mCherry was used. This construction created a 249-nucleotide deletion in the A137R ORF (amino acid residues 1 to 85) (<figref idref="DRAWINGS">FIG. <b>1</b></figref>). Recombinant transfer vector p72mCherry&#x394;A137R was obtained by DNA synthesis (Epoch Biosciences, Bothwell, Wash., USA). Macrophage cell cultures were infected with ASFV-G and transfected with p72mCherry&#x394;A137R. Recombinant viruses representing independent primary plaques were purified to homogeneity by successive rounds of plaque assay purification. The recombinant virus was obtained after 9 successive plaque purification events on monolayers of primary swine macrophage cell cultures.</p><heading id="h-0011" level="1">Example 3</heading><p id="p-0065" num="0064">Full Genome Sequence Analysis of ASFV-G &#x394;A137R Relative to Parental ASFV-G.</p><p id="p-0066" num="0065">To evaluate the accuracy of the genetic modification and the integrity of the genome of the recombinant virus, full genome sequences of ASFV-G &#x394;A137R and parental ASFV-G were obtained using Next Generation Sequencing (NGS) and compared. As a first step, a full-length genome comparison between the parental ASFV-G laboratory strain used to construct the ASFV-G &#x394;A137R mutant virus and the original ASFV Georgia 2007/1 (Chapman et al, Emerg. Infect. Dis., (2001) 17:599-605; GenBank accession FR682468.2) was performed. ASFV DNA was obtained from the cytoplasm of infected cells using the Trizol method (Life Technologies, Grand Island, N.Y., USA). DNA concentration was determined using the Qubit&#xae; dsDNA HS assay kit (Life Technologies) and read on a Qubit&#xae; 2 Flourometer (Life Technologies). In Brief, the viral DNA was sheared using enzymatic reactions assessed for the distribution of size fragmentation, then ligation of identifying barcodes using an adapter sequence were added to the DNA fragments. Using a Pippin Prep&#x2122; (Sage Science, Beverly, Mass.) the required size range of the library was collected, and normalized. We then used this DNA library for NGS sequencing using the NextSeq (Illumnia, San Diego, Calif.) following the manufactures protocol. Sequence analysis was performed using CLC Genomics Workbench software (CLCBio, Waltham, Mass.).</p><p id="p-0067" num="0066">The following differences were observed between these two viruses (nucleotide positions are provided based on ASFV Georgia 2007/1, GenBank accession FR682408.2 (i) one nucleotide insertions an A at position 1363, (ii) two deletions a G at position 19792, GT at 2008 and a G at 21797. (iii) single nucleotide variants 98378 and 190543 have an A to G change [mark in this case and all following A is in the vaccine described here and G is the reference], an C to G change at position 167188. Position 93878 is in ORF B438L but is a silent mutation that does not affect the amino acid sequence of the protein product. The change at 167188 changes protein E119L from an Alanine to Proline. None of the other changes described here affect any known ORF and are located in non-coding areas of the genome.</p><p id="p-0068" num="0067">To determine if the recombinant virus acquired additional genetic changes from the parent strain, a full-length genome comparison between ASFV-G &#x394;A137R and the parental ASFV-G was performed. The DNA sequence assemblies of ASFV-G &#x394;A137R and ASFV-G revealed a deletion of 249 nucleotides in A137R gene corresponding with the introduced modification. The consensus sequence of the ASFV-G &#x394;A137R genome showed an insertion of 3944 nucleotides in A137R gene corresponding to the p72-mcherry cassette sequence introduced to generate a 249-nucleotide deletion in the targeted gene. Besides the insertion of the cassette, no additional differences were observed between ASFV-G &#x394;A137R and ASFV-G genomes. In summary, ASFV-G &#x394;A137R virus did not accumulate any significant mutations during the process of homologous recombination and plaque purification.</p><heading id="h-0012" level="1">Example 4</heading><p id="p-0069" num="0068">Assessment of ASFV-G &#x394;A137R Virulence in Swine.</p><p id="p-0070" num="0069">Animal experiments were performed under biosafety level 3 conditions in the animal facilities at PIADC following a protocol approved by the Institutional Animal Care and Use Committee.</p><p id="p-0071" num="0070">ASFV-G &#x394;A137R was assessed for its virulence phenotype relative to the virulent parental ASFV-G virus using 80-90-pound commercial breed swine. Five pigs were inoculated intramuscularly (IM) either with 10<sup>2</sup>, of ASFV-G &#x394;A137R or with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G virus. Clinical signs (anorexia, depression, fever, purple skin discoloration, staggering gait, diarrhea and cough) and changes in body temperature were recorded daily throughout the experiment. In protection experiments animals were IM inoculated with 10<sup>2 </sup>HAD<sub>50 </sub>and 28 days later IM challenged with 10<sup>2 </sup>HAD<sub>50 </sub>of parental virulent ASFV Georgia 2007 strain. Presence of clinical signs associated with the disease was performed as described earlier.</p><p id="p-0072" num="0071">All pigs inoculated via IM with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G exhibited increased body temperature (&#x3e;104&#xb0; F.) by 3 to 4 days post-infection. Pigs presented clinical signs associated with the disease including anorexia, depression, purple skin discoloration, staggering gait and diarrhea (Table 1). Signs of the disease aggravated progressively over time and animals either died or were euthanized in extremis by days 7 or 9 post-infection. Conversely, animals inoculated via IM with 10<sup>2 </sup>of ASFV-G &#x394;A137R did not present any signs of clinical disease during the entire observation period (21 days). Therefore, deletion of A137R gene produced a complete attenuation of the parental virulent ASFV-G. That the ASFV-G &#x394;A137R mutant was attenuated was surprising as we have deleted many single genes with unknown function, and no observed changes in virulence resulted. All animals in the Mock vaccinated group were euthanized due to humanitarian reasons following the corresponding IACUC protocol.</p><p id="p-0073" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="273pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Swine survival and fever response following infection with</entry></row><row><entry>10<sup>2 </sup>HAD<sub>50 </sub>doses of ASFV-G-&#x394;A137R or parental ASFV-G.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="140pt" align="left"/><colspec colname="1" colwidth="133pt" align="center"/><tbody valign="top"><row><entry/><entry>Fever</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Virus</entry><entry>No. of</entry><entry>Mean time</entry><entry>No. of days</entry><entry>Duration</entry><entry>Maximum</entry></row><row><entry>and dose</entry><entry>survivors/</entry><entry>to death</entry><entry>to onset</entry><entry>No. of days</entry><entry>daily temp</entry></row><row><entry>(HAD<sub>50</sub>)</entry><entry>total</entry><entry>(days &#xb1; SD)</entry><entry>(days &#xb1; SD</entry><entry>(days &#xb1; SD)</entry><entry>(&#xb0; F. &#xb1; SD)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>ASFV-G</entry><entry>0/5</entry><entry>7 (0) <sup>(1)</sup></entry><entry>4.6 (0.55)</entry><entry>2.4 (0.55)</entry><entry>105.52 (0.79)</entry></row><row><entry>ASFV-G-&#x394;A137R</entry><entry>5/5</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>&#x2002;103.4 (0.46)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0013" level="1">Example 5</heading><p id="p-0074" num="0072">Protective Effect of ASFV-G &#x394;A137R Against Challenge with Parental ASFV-G.</p><p id="p-0075" num="0073">Because pigs inoculated via IM with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G &#x394;A137R survived the infection without signs of the disease, groups of animals (n=5) inoculated with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G &#x394;A137R were challenged via IM with 10<sup>2 </sup>HAD<sub>50 </sub>of parental ASFV-G at day 28 post-inoculation (homologous challenge). Five naive animals that were challenged using the same route and dose served as a non-inoculated/challenged control group. All animals were IM vaccinated with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G &#x394;A137R and challenged IM 28 days later with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G virus. All animals in the Mock vaccinated group were euthanized due to humanitarian reasons following the corresponding IACUC protocol. All animals in the ASFV-G &#x394;A137R vaccinated group remain clinically normal during the observational period of 21 days after the challenge.</p><p id="p-0076" num="0074">The five ASFV-G &#x394;A137R-inoculated and challenged animals remained completely asymptomatic during all the observational period (21 days) (Table 2). All the animals in the mock inoculated/challenged control group developed disease with a clinical course similar to that observed in animals inoculated with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G (see above). Therefore, ASFV-G &#x394;A137R is able to induce protection against the presentation of clinical disease when challenged with the highly virulent parental virus.</p><p id="p-0077" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="273pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Swine survival and fever response in animals challenged with</entry></row><row><entry>ASFV-G virus at 28 days post-ASFV-G-&#x394;A137R infection.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="140pt" align="left"/><colspec colname="1" colwidth="133pt" align="center"/><tbody valign="top"><row><entry/><entry>Fever</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry>No. of</entry><entry>Mean time</entry><entry>No. of days</entry><entry>Duration</entry><entry>Maximum</entry></row><row><entry>Virus</entry><entry>survivors/</entry><entry>to death</entry><entry>to onset</entry><entry>No. of days</entry><entry>daily temp</entry></row><row><entry>(10<sup>2 </sup>HAD<sub>50</sub>)</entry><entry>total</entry><entry>(days &#xb1; SD)</entry><entry>(days &#xb1; SD</entry><entry>(days &#xb1; SD)</entry><entry>(&#xb0; F. &#xb1; SD)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>Mock</entry><entry>0/5</entry><entry>7 (0) <sup>(1)</sup></entry><entry>4.2 (0.45)</entry><entry>2.8 (0.45)</entry><entry>105.98 (0.94)</entry></row><row><entry>ASFV-G-&#x394;A137R</entry><entry>5/5</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>102.22 (1.06)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0078" num="0075">In summary, here we present evidence that deletion of the A137R gene drastically alters virulence of ASFV-G producing a completely attenuated virus named ASFV-G &#x394;A137R. Animals immunized with ASFV-G &#x394;A137R were protected against challenge with the virulent parental ASFV-G.</p><heading id="h-0014" level="1">Example 6</heading><p id="p-0079" num="0076">The Ability of ASFV-G-A137R to Grow in Swine Macrophages</p><p id="p-0080" num="0077">In vitro growth characteristics of ASFV-G-&#x394;A137R were evaluated in primary swine macrophage cell cultures, the primary cell targeted by ASFV during infection in swine and compared relative to parental ASFV-G in multistep growth curves (<figref idref="DRAWINGS">FIG. <b>2</b></figref>). Cell cultures were infected at a MOI of 0.01 and samples were collected at 2, 24, 48, 72 and 96-hours post-infection (hpi). Results demonstrated that ASFV-G-&#x394;A137R displayed a growth kinetic significantly decreased when compared to parental ASFV-G. ASFV-G-&#x394;A137R yields are approximately 10-100-fold lower than those of ASFV-G depending on the time point considered.</p><p id="p-0081" num="0078">Therefore, deletion of the A137R gene significantly decreased the ability of ASFV-G-&#x394;A137R, relative to the parental ASFV-G isolate, to replicate in vitro in primary swine macrophage cell cultures.</p><heading id="h-0015" level="1">Example 7</heading><p id="p-0082" num="0079">ASFV-G-&#x394;A137R Infected Animals Shed Vaccine Virus</p><p id="p-0083" num="0080">In the above example where different groups of five pigs were infected IM with 10<sup>2 </sup>HAD<sub>50 </sub>of ASFV-G-&#x394;A137R, a mock infected animal was cohabitating in each of the groups as sentinel to detect the potential virus shedding from the infected animals. All sentinel animals remained clinically normal, although the presence of ASFV-G-&#x394;A137R in sentinel animals indicates the presence of virus shedding and explains the late rise of ASFV specific antibodies by day 28 post infection.</p><heading id="h-0016" level="1">Example 8</heading><p id="p-0084" num="0081">Host Antibody Response in Animals Infected with ASFV-G-&#x394;A137R</p><p id="p-0085" num="0082">All animals infected with ASFV-G-&#x394;A137R, regardless of the dose of virus received possessed similar high titers of circulating anti-ASFV antibodies. Antibody response, mediated by IgG isotypes, starts being detected in three of the animals by day 11 pi and 4 of the animals day 14 pi and in all of the animals by day 21 and was also observed in all five animals day 28 pi reaching maximum levels in all animals inoculated with ASFV-G-&#x394;A137R. Therefore, there is a close correlation between presence of anti-ASFV antibodies at the moment of the challenge and protection. It should be mentioned that a low level of antibodies was detected in one of the serum samples obtained from one of the sentinel animals (<figref idref="DRAWINGS">FIG. <b>3</b></figref>).</p><heading id="h-0017" level="1">Example 9</heading><p id="p-0086" num="0083">Induction of Sterile Immunity</p><p id="p-0087" num="0084">Using an A137R specific real time PCR to specifically detect only challenge virus (which allows the detection of approximately 10 HAD<sub>50</sub>) all blood samples tested negative for the presence of challenge virus. Furthermore, tonsils and spleen samples were obtained from all animals at the end of the observational period (21 days post challenge) and tested for the presence of virus by virus isolation in swine macrophage cultures. Most of the animals in each group showed presence of infectious virus either in tonsils or spleen (data not shown). All positive samples were then assessed using the A137R specific real time PCR detecting the presence of the challenge virus in only one spleen belonging to one of the animals initially infected with 10<sup>2 </sup>HAD<sub>50</sub>/ml of ASFV-G-&#x394;A137R. These results suggest that replication of challenge virus was absent in all infected animals receiving 10<sup>2 </sup>HAD<sub>50</sub>/ml of ASFV-G-&#x394;A137R.</p><p id="p-0088" num="0085">In summary, sterile immunity (immunity that doesn't allow the replication of challenge virus) was achieved in animals vaccinated with 10<sup>2 </sup>HAD<sub>50</sub>/ml of ASFV-G-&#x394;A137R.</p><p id="p-0089" num="0086">While the invention has been described with reference to details of the illustrated embodiments, these details are not intended to limit the scope of the invention as defined in the appended claims. The embodiments of the disclosure in which exclusive property or privilege is claimed is defined as follows:</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000967A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A genetically modified virus, wherein the virus genome comprises a viral genome at least 99% identical to SEQ ID NO: 2.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The virus of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the viral genome comprises a viral genome at least 99.8% identical to SEQ ID NO:2.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The virus of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the viral genome comprises SEQ ID NO: 2</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. A vaccine composition against African Swine Fever Virus (ASFV), comprising the genetically modified virus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The vaccine composition of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the ASFV is ASFV-Georgia 2007 isolate (ASFV-G).</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. A method for the protection of swine against ASFV, comprising administering to a swine a live attenuated vaccine comprising the genetically modified virus of <claim-ref idref="CLM-00001">claim 1</claim-ref> in an amount effective to protect said swine from clinical ASFV disease.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The method of <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein the ASFV is ASFV-G.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The method of <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein the amount effective to protect said swine from clinical ASFV disease is a vaccine comprising 10<sup>2</sup>-10<sup>6 </sup>HAD<sub>50 </sub>of the genetically modified virus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. A recombinant ASFV mutant virus, comprising a synthetic mutation in the A137R open reading frame or in a regulatory element controlling the expression of the A137R protein, resulting in a non-functional genomic A137R gene.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the synthetic mutation is a deletion mutation resulting the deletion of one or more nucleotides between positions 55531 and 55779 of SEQ ID NO:1.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the synthetic mutation is a frameshift mutation, insertion mutation, nonsense mutation of one or more nucleotides between positions 55531 and 55779 of SEQ ID NO:1.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the mutant ASFV is an ASFV-Georgia isolate.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the mutant ASFV comprises a genome at least 95% identical to SEQ ID NO: 2.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the mutant ASFV comprises a genome at least 99% identical to SEQ ID NO: 2.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. A vaccine composition against ASFV-G, comprising the recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A method for the protection of swine against ASFV, comprising administering to a swine a live attenuated vaccine comprising the recombinant virus of <claim-ref idref="CLM-00009">claim 9</claim-ref> in an amount effective to protect said swine from clinical ASFV disease.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the ASFV is ASFV-G.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the amount effective to protect said swine from clinical ASFV disease is a vaccine comprising at least 10<sup>2 </sup>HAD<sub>50 </sub>of the genetically modified virus of <claim-ref idref="CLM-00009">claim 9</claim-ref>.</claim-text></claim></claims></us-patent-application>